Next Article in Journal
Chemical Analysis of Minor Bioactive Components and Cannabidiolic Acid in Commercial Hemp Seed Oil
Next Article in Special Issue
Imipramine Inhibits Migration and Invasion in Metastatic Castration-Resistant Prostate Cancer PC-3 Cells via AKT-Mediated NF-κB Signaling Pathway
Previous Article in Journal
Synthesis and Antiviral Evaluation of 3′-Fluoro-5′-norcarbocyclic Nucleoside Phosphonates Bearing Uracil and Cytosine as Potential Antiviral Agents
Previous Article in Special Issue
Design, Synthesis and Preliminary Biological Evaluation of Benzylsulfone Coumarin Derivatives as Anti-Cancer Agents
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 16
10.3390/molecules25163709
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Cytotoxic Activity of Novel C-23-Modified Asiatic Acid Derivatives

by
Yi-hong Lu
1,2,
Ming-cang Chen
1,
Fang Liu
1,2,
Zhou Xu
1,
Xiao-ting Tian
1,2,
Yang Xie
1,* and
Cheng-gang Huang
1,2,*
1
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China
2
School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China
*
Authors to whom correspondence should be addressed.
Molecules 2020, 25(16), 3709; https://doi.org/10.3390/molecules25163709
Submission received: 10 June 2020 / Revised: 5 August 2020 / Accepted: 8 August 2020 / Published: 14 August 2020
(This article belongs to the Collection Efficient Pharmaceutical and Chemical Approaches for Anticancer Therapy: Design, Preliminary Evaluations, and Further Developments)
Browse Figures
Versions Notes

Abstract

:
We selectively oxidized the C-23 hydroxyl group in an asiatic acid (AA) derivative and then, for the first time with AA, modification of the C-23 carboxyl group was conducted to synthesize a series of new AA derivatives. The evaluation of their cytotoxic activities against two human cancer cell lines (SKOV-3 and HCT116) using the MTT assay in vitro revealed a distinctive structure activity relationship (SAR) associated with the intramolecular hydrogen bonding of the amide moiety at C-23. According to the established SAR, the cytotoxic activities of four promising compounds were then evaluated against MCF-7, A549, A2780, HepG2 and HL-60 cancer cell lines. Compound 10 had the best cytotoxic activity among all tested derivatives in the HL-60 cell line, giving IC50 = 0.47 μM, while showing no cytotoxic effect against human normal cells (HUVEC).

Graphical Abstract

1. Introduction

Natural products are a major source of lead compounds for new therapeutic agents [1,2]. In recent years, triterpenoids, as one of the largest classes of natural products, have been frequently reported for their remarkable bioactivities including anticancer effects; in particular, triterpenoid acids, such as oleanolic acid (OA) [3], asiatic acid (AA) (Figure 1) [4,5] and maslinic acid (MA) [6,7], have received increased attention.
Asiatic acid (AA, 2α,3β,23-trihydroxyurs-12-ene-28-oic acid), one of the active pentacyclic triterpenoid acids, is usually prepared from the hydrolysis of asiaticoside, which is extracted from the traditional Chinese medicine herb Centella asiatica [8]. The primarily usage of AA is for treating skin diseases [9,10]. In recent years, other noteworthy bioactivities have been reported, including hepatoprotective [11], antidiabetic [12], anti-inflammatory [13,14] and especially antitumor activity. AA inhibits proliferation of various cancer cell lines and induces apoptosis [4,5,15].
Previously, AA has been modified to improve its anticancer effects and other bioactivities. Li et al. reported that oxidation at C-11 to form α–β unsaturated ketone, and the introduction of anilines to form amide bond at C-28, could improve the anticancer activity in vitro [16]. Huang et al. synthesized AA based 1,2,3-triazole derivatives which were subjected to a cell-based NF-κB inhibition screening assay and MTT assay [17]. Huang et al. also synthesized AA derivatives containing α-aminophosphonate as antitumor agents [18]. Jing et al. introduced various amino acid esters to form amide bonds at C-28 [19]. Sommerwerk et al. modified C-28 with different quinolinyl amides [20]. Gonçalves et al. changed the A-ring framework to synthesize active compounds with a pentameric A-ring containing an α-β-unsaturated carbonyl group [21].
However, many modifications focused on the C-28 carboxyl group; the C-2, C-3 and C-23 hydroxyl groups have rarely been modified, except for the acetylation of all three hydroxyl groups due to the poor reaction selectivity of the three hydroxyl groups. In some studies, the C-3 and C-23 hydroxyl groups were protected as a ketal, and thus, modification at the 2α-hydroxy or further modification at the 3β,23-dihydroxy could be carried out [21,22,23,24,25,26]. Nevertheless, due to the poor reaction selectivity between the C-3 and C-23 hydroxyl groups, the respective modification of the C-3 and C-23 hydroxyl groups has rarely been reported [25].
Referring to other triterpenoid acids with a similar structure, an di-O-acetylated benzylamide maslinic acid derivative, named EM2 (Figure 1), exhibited rather low EC50 values (EC50 = 0.5 μM) against human ovarian cancer cells (A2780) [20,27]. Another natural triterpenoid acid, gypsogenin (Figure 1), is extracted from Gypsophila [28], and contains a natural C-23 aldehyde group, which inhibited several cancer cell lines [29]. Heller et al. conducted oxidation on the C-23 aldehyde group to synthesize 23-carboxyl and 23-methylester gypsogenin derivatives, which showed inhibition against several cancer cell lines [30]. Wu et al. synthesized bisamide gypsogenin derivatives at the C-23 and C-28 positions, which showed good antitumor activity. A 23-oicacid-28amide gypsogenin derivative gave IC50 = 2.2 μΜ for HepG-2 cell line [31].
Taking into account these good results, in this paper we introduced benzyl amine to form amide bonds at C-28, and conducted rather highly selective oxidation at the C-23 hydroxyl group to transform 23-hydroxy into aldehyde and then further into carboxyl functionalities. Afterwards, modification on the C-23 carboxyl group was conducted for the first time to synthesize a series of novel AA derivatives. The cytotoxic activities against ovarian (SKOV-3) and colon (HCT-116) cancer cell lines of these derivatives were evaluated using the MTT assay in vitro. According to the structure activity relationship (SAR) established on the cytotoxic activities against SKOV-3 and HCT-116 cells, the cytotoxic activities of four promising compounds were then evaluated against additional cancer cell lines (MCF-7, A549, A2780, HepG2 and HL-60).

2. Results and Discussion

2.1. Chemistry

The synthetic route of the newly synthesized AA derivatives is shown in Scheme 1. To protect the C-3 and C-23 hydroxyl groups, AA as the starting material was reacted with 2,2-dimethoxypropane to selectively form a six-membered ketal ring in the initial framework, affording crude product compound 1 in high yield. We introduced benzyl amine to form an amide bond at C-28, thereby obtaining compound 2. After methylation at the 2α-hydroxy, the C-3 and C-23 hydroxyl groups were recovered in compound 4. Critically, to obtain compound 6, a low concentration DCM solution of Dess–Martin Periodinane (DMP) was added to the solution of compound 4 at an appropriately slow speed, because DMP prefers to oxidize the C-23 hydroxyl group, but the production of the side product, compound 5, was inevitable. It should be noted that DMP gradually loses its efficacy at room temperature. We adapted a similar oxidation method carried out on gypsogenin [30] to further transform the 23-aldehyde into the 23-carboxyl and thereby, obtained compound 7 in 93% yield. Compound 9 was prepared by methylation of 23-carboxyl of compound 7 with CH3I. Then, oxidation of the C-3 hydroxyl group of compound 9 was carried out by employing pyridinium chlorochromate (PCC) to generate compound 11. Compounds 13 and 14 were prepared by the introduction of various amines at the 23-carboxyl group in compounds 7 and 8 in yields between 45–84%. The structures of all new compounds were fully confirmed by 1H-NMR, 13C-NMR and high resolution mass spectrometry (HRMS).

2.2. Biology

To establish a SAR of the C-3 (R2) and C-23 (R1) of the AA derivatives, new compounds were subjected to MTT assays to evaluate their in-vitro antiproliferative activities against ovarian (SKOV-3) and colon (HCT-116) cancer cell lines, the IC50 values (the concentration that inhibits 50% of cell growth) of which are summarized in Table 1. Doxorubicin was used as the positive drug.
For compounds 13f–i, with the introduction of various amino acid esters at C-23, their cytotoxic activities against the HCT116 cell line decreased progressively along with that of the larger group at C-23. In addition, the cytotoxic activities of compound 13f against the SKOV-3 cell line improved considerably, and yet compound 13h was not active. These combined results suggested that the smaller amide moiety at C-23 led to increased cytotoxic activity.
For the modification at C-3, compounds 9 and 10 were 8- and 23-fold more active, respectively, than AA against HCT116 cell line, and compound 9 was 3-fold more active than AA against SKOV-3 cell line, while the 3β-hydroxy oxidation product, compound 11, lost activity towards both cell lines. In addition, compounds 6 and 12 were both much more active than compound 5 against the HCT116 cell line. These results indicated that the carbonyl moiety at C-3 decreased the cytotoxicity.
We studied the intramolecular hydrogen bonds of the 23-amide AA derivatives via exhaustive NMR characterization (Table 2). The assignments of C-2, C-3, C-23 and NH-23 of compounds 13b and 14b were unambiguously achieved by a combination of 1H, 13C, DEPT, HSQC and HMBC experiments (see the Supplementary Materials). The assignments of compounds 13a, c–j and 14a, c–j were then accomplished by analogy. The effect of intermolecular hydrogen bonding depends on the concentration of the NMR sample. In addition, the chemical shift is badly influenced by the intermolecular hydrogen bonding in the 1H-NMR experiment, while it is barely influenced in the 13C-NMR experiment. To minimize the effect of intermolecular hydrogen bonding in the 1H-NMR experiment, NMR titration (see the Supplementary Information) was conducted in compounds 13b and 14b to select the proper concentration, and then the 1H-NMR signals of NH-23 of compounds 13 and 14 were all recorded at the same concentration (4.85 mM). The 13C-NMR signals of C-2, C-3 and C-23 were recorded without the limitation of concentration.
According to Table 2, after the acetylation of 3β-hydroxy, the chemical shift at C-2, C-3, C-23 and NH-23 had changed because the loss of 3β-OH donor influenced or deprived the intramolecular hydrogen bonds. Thus, we could deduce the hydrogen bond from the change of the chemical shift (Table 2). Specifically, we could deduce the hydrogen bond connecting 3β-OH donor with 2α-OCH3 acceptor from the change of the chemical shift at C-2 and C-3. We could deduce the hydrogen bond connecting 3β-OH donor with 23-carbonyl acceptor from the change of the chemical shift at C-23. Additionally, we could deduce the hydrogen bond connecting NH-23 donor with 3β-OH acceptor from the change of the chemical shift at NH-23. Further, the chemical shifts of two amide hydrogen atoms at NH2-23 in compound 14a were apparently different, which revealed the hydrogen bond connecting NH-23 donor with 3β-acetoxy acceptor. By analogy, it was possible to form the hydrogen bonds in 3β-acetoxy derivatives 14. To sum up, the hydrogen bonding modes A and B (Figure 2) for 3β-hydroxy derivatives 13 were supposed to exist in the solvent at the same time, and mode C for 3β-acetoxy derivatives 14 may exist.
Surprisingly, for compounds 13a–i and 14a–i, we found that the 23-amide AA derivatives which showed rather good cytotoxic activities, could fix the amide hydrogen atom in the AA skeleton through intramolecular hydrogen bonding, no matter what the mode (A, B or C). Comparatively, the 23-amide AA derivatives which were not active, were unable to fix the amide hydrogen atom in the AA skeleton. Specifically, for compounds 13, according to Table 2, the amide hydrogen atom at C-23 of 13b–h could be fixed in the AA skeleton through mode A or B, the amide hydrogen atom of 13i could be fixed through mode B, and the amide hydrogen atom of 13a could be fixed through mode A. After the acetylation of 3β-hydroxy, the cytotoxic activities of compounds 14 against HCT116 cell line decreased progressively along with that of the larger group at C-23, and 14c–i even lost its cytotoxic activities, probably because the steric hindrance of the amide moiety at C-23 blocked the intramolecular hydrogen bond in mode C. Therefore, compounds 13a–g, i and 14a which fixed the amide hydrogen atom in the AA skeleton, exhibited increased cytotoxic activity against HCT116 cell line. Similarly, compounds 13e–f and 14a showed rather good cytotoxic activities against the SKOV-3 cell line. Comparatively, compounds 14c–i, which were unable to fix the amide hydrogen atom in the AA skeleton, were not active in either cell line. Additionally, compounds 9, 10, 13j and 14j without the amide hydrogen atom at C-23 exhibited a considerable improvement in the cytotoxic activities against the HCT116 cell line. To summarize, the cytotoxicity results suggested that the freely rotating amide hydrogen atom at C-23 led to the loss of cytotoxic activity.
Hence, the cytotoxic activities of compounds 10, 13k, 14j and 14k without any amide hydrogen atom at C-23 were evaluated in a panel of additional five cancer cell lines (MCF-7, A549, A2780, HepG2 and HL-60) using the MTT assay (Table 3). 3β-acetoxy derivative 14k was more active than 3β-hydroxy derivative 13k against A549, A2780, HL-60 and MCF-7 cell lines, and was commensurately active with 14k against HepG2 cell lines. Combined with the results against the HCT116 cell line shown in Table 1, 3β-acetoxy derivatives 10 and 14j exhibited increased activity compared to the corresponding 3β-hydroxy derivatives 9 and 13j. These combined results suggested that 3β-acetoxy moiety improved the cytotoxic activity, in the case of a lack of amide hydrogen atoms at C-23.
Additionally, the cytotoxic activities of compounds 10, 14j and 14k were evaluated against one human normal cell line (HUVEC) using CCK-8 assay (Table 3). Compounds 10, 14j and 14k at the concentrations of 125, 25, 5, 1, 0.2, 0.04 μM all showed no cytotoxic effect on HUVEC cell viability (Figure 3). These results indicated that the cytotoxicity of compounds 10, 14j and 14k against cancer cells was much higher than that against HUVEC normal cells.

3. Materials and Methods

3.1. Chemistry

3.1.1. General

Asiatic acid was purchased from Xi’an Shouhe Biotechnology Co., Ltd. All reagents and solvents were obtained from Sinopharm. IR spectra were recorded on a THERMO IS5. NMR spectra (1H, 13C, DEPT, HSQC and HMBC) were recorded on a Bruker Ascend-400 400 MHz or Bruker Ascend-500 500 MHz at room temperature. HRMS were recorded on an Agilent 6530-Q-TOF mass spectrometer equipped with an Agilent 1260-HPLC.

3.1.2. α-Hydroxy-3β,23-Isopropylidenedioxy-Urs-12-Ene-28-Oic Acid (1)

Under a nitrogen atmosphere, AA (480 mg, 1 mmol) was dissolved in dry acetone (50 mL). 2,2-dimethoxypropane (150 μL, 1.2 mmol) and TsOH·H2O (17 mg, 0.1 mmol) was added, stirring at room temperature overnight. Evaporated 2,2-dimethoxypropane and acetone, neutralized the reaction mixture with a saturated solution of sodium bicarbonate and extracted the solution with DCM (dichloromethane). The organic phase was washed with brine, dried over Na2SO4 and concentrated to dryness under vacuum to obtain the crude product 1 as a white solid (449 mg, 85%). IR (CH2Cl2, cm−1) νmax: 1033, 1190, 1391, 1454, 1552, 1648, 1689, 2871, 2939, 3199, and 3466 [22]. 1H-NMR (400 MHz, CDCl3) δ 5.25 (t, J = 3.6 Hz, 1H, H-12), 3.81 (td, J = 10.2, 4.5 Hz, 1H, H-2), 3.58–3.44 (m, 2H, H-23), 3.34 (d, J = 9.6 Hz, 1H, H-3), 1.27 (d, J = 2.2 Hz, 3H), 1.11 (s, 3H), 1.07 (s, 3H), 1.06 (s, 3H), 0.87 (d, J = 6.4 Hz, 3H), 0.76 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 183.63 (C-28), 137.85 (C-13), 125.45 (C-12), 99.65 (3β,23-ketal), 82.10 (C-3), 72.67 (C-23), 65.26 (C-2), 52.44, 51.38, 47.87, 47.57, 46.49, 41.94, 39.55, 39.01, 38.79, 38.01, 36.92, 36.66, 32.30, 30.57, 29.74, 27.92, 23.97, 23.67, 23.15, 21.20, 19.43, 17.96, 17.50, 16.99, 16.95, 13.49. HRMS (ESI) observed C33H51O5 527.3742 (M-H−) requires 527.3742.

3.1.3. α-Hydroxy-3β,23-Isopropylidenedioxy-Urs-12-Ene-28-Benzylamide (2)

To a solution of compound 1 (1.1 g, 2 mmol) in dry DMF (30 mL), HATU (1.17 g, 3 mmol), benzyl amine (0.5 mL, 4 mmol) and DIPEA (65 μL, 4 mmol) was added, stirring at 60 °C overnight. The reaction mixture was poured into the brine, and extracted with ethyl acetate (100 mL × 3). The organic phase was washed with brine (200 mL × 3), dried over Na2SO4 and concentrated to dryness under vacuum. The crude product was purified by column chromatography over silica gel ((200–300 mesh) using hexane/AcOEt (5:2) to afford compound 2 as a white solid (766 mg, 62%). IR (CH2Cl2, cm−1) νmax: 3367, 2920 (C=C-H), 1639 (C=O), 1520 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.18 (m, 1H, NH-28), 5.24 (t, J = 3.5 Hz, 1H, C-12), 4.51 (dd, J = 14.5, 5.9 Hz, 1H, CH2-N-28), 4.15 (dd, J = 14.8, 4.7 Hz, 1H, CH2-N-28), 4.10 (q, J = 7.2 Hz, 1H), 3.79 (td, J = 10.3, 4.5 Hz, 1H, H-2), 3.59–3.44 (m, 2H, H-23), 3.32 (d, J = 9.6 Hz, 1H, H-3), 2.06 (s, 1H), 1.12 (s, 3H), 1.09 (s, 3H), 1.01 (s, 3H), 0.86 (d, J = 6.5 Hz, 3H), 0.69 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.80 (C-28), 139.76, 138.31, 128.67, 127.89, 127.41, 125.39 (C-12), 99.60 (3β,23-ketal), 82.06 (C-3), 72.64 (C-23), 65.21 (C-2), 53.96, 51.34, 47.72, 47.56, 46.53, 43.68, 42.50, 39.75, 39.60, 39.06, 37.89, 37.20, 36.89, 32.19, 30.86, 29.75, 27.83, 24.80, 23.33, 23.18, 21.21, 19.41, 17.92, 17.47, 17.19, 16.90, 13.51. HRMS (ESI) observed C40H60NO4 618.4518 (MH+) requires 618.4517.

3.1.4. α-Methoxy-3β,23-Isopropylidenedioxy-Urs-12-Ene-28-Benzylamide (3)

Under a nitrogen atmosphere, compound 2 (3.3 g, 5.3 mmol) was dissolved in dry DMF (20 mL), and NaH (120 mg, 8 mmol) was added at 0 °C. After stirring for 20 min, CH3I (1.6 mL 25 mmol) was added in room temperature and stirring was continued for 30 min. The reaction mixture was poured into the brine, and extracted with ethyl acetate (100 mL × 3). The organic phase was washed with brine (200 mL × 3), dried over Na2SO4 and concentrated to dryness under vacuum to obtain the crude product 3 as a white solid (3.25 g, 97%). IR (CH2Cl2, cm−1) νmax: 3376, 2921 (C=C-H), 1640 (C=O), 1522 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.17 (t, J = 5.3 Hz, 1H, NH-28), 5.22 (t, J = 3.5 Hz, 1H, H-12), 4.52 (dd, J = 14.5, 5.9 Hz, 1H, CH2-N-28), 4.18 (dd, J = 14.5, 4.5 Hz, 1H, CH2-N-28), 3.54–3.43 (m, 3H, H-23 and H-3), 3.41 (s, 3H, OCH3-2), 3.36 (td, J = 10.2, 4.2 Hz, 1H, H-2), 2.07 (dd, J = 12.6, 4.4 Hz, 1H), 1.09 (d, J = 1.6 Hz, 6H), 0.99 (s, 3H), 0.67 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.70 (C-28), 139.75, 138.35, 128.63, 127.89, 127.37, 125.33 (C-12), 99.16 (3β,23-ketal), 81.44 (C-3), 74.32 (C-2), 72.62 (C-23), 57.63 (OCH3-2), 53.92, 51.00, 47.69, 47.58, 44.91, 43.66, 42.47, 39.72, 39.55, 39.05, 37.82, 37.35, 37.22, 32.20, 30.87, 29.88, 27.83, 26.91, 24.79, 23.31, 23.18, 21.22, 19.27, 17.87, 17.35, 17.18, 16.87, 13.73. HRMS (ESI) observed C41H62NO4 632.4673 (MH+) requires 632.4673.

3.1.5. α-Methoxy-3β,23-Dihydroxy-Urs-12-Ene-28-Benzylamide (4)

Compound 3 (2.5 g, 4 mmol) was stirred with 40 mL of dilute aqueous HCl (1 M) for 30 min. The reaction mixture was neutralized with a saturated solution of sodium bicarbonate and extracted with DCM. The organic phase was washed with brine, dried over Na2SO4 and concentrated to dryness under vacuum to obtain the crude product. The crude product was purified by column chromatography over silica gel ((200–300 mesh) using hexane/AcOEt (3:2) to afford compound 4 as a white solid (2.32 g, 98%). IR (CH2Cl2, cm−1) νmax: 3421, 2920 (C=C-H), 1637 (C=O), 1522 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.24–6.09 (m, 1H, NH-28), 5.24 (t, J = 3.5 Hz, 1H, H-12), 4.55 (dd, J = 14.5, 5.9 Hz, 1H, CH2-N-28), 4.20 (dd, J = 14.5, 4.5 Hz, 1H,) CH2-N-28, 4.13 (q, J = 7.1 Hz, 1H), 3.64 (d, J = 10.8 Hz, 1H, H-23), 3.46 (d, J = 9.5 Hz, 1H, H-23), 3.40 (s, 3H, OCH3-2), 3.39 (dd, 1H, H-3), 3.30 (ddd, J = 11.2, 9.5, 4.3 Hz, 1H, H-2), 2.75 (br s, 3H), 2.11 (dd, J = 12.4, 4.3 Hz, 1H), 2.06 (s, 1H), 1.10 (s, 3H), 1.00 (s, 3H), 0.88 (s, 3H), 0.86 (d, J = 6.5 Hz, 3H), 0.71 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.86 (C-28), 139.97, 138.32, 128.67, 127.92, 127.41, 125.33 (C-12), 78.36 (C-2), 78.36 (C-3), 69.60 (C-23), 56.58 (OCH3-2), 53.93, 48.34, 47.73, 47.42, 43.71, 42.57, 42.36, 41.93, 39.70, 39.58, 39.06, 37.88, 37.24, 32.42, 30.86, 27.80, 24.83, 23.42, 23.34, 21.21, 18.05, 17.23, 17.19, 17.07, 12.79. HRMS (ESI) observed C38H58NO4 592.4373 (MH+) requires 592.4360.

3.1.6. α-Methoxy-3,23-Dioxo-Urs-12-Ene-28-Benzylamide (5)

Fresh DCM (50 mL × 3) suspension of Dess-Martin Periodinane (283 mg × 3, 2 mmol) added dropwise in three separate times to compound 4 (1 g, 1.7 mmol) dissolved in dry DCM (20 mL), until starting material almost consumed. The reaction mixture was poured into aqueous solution of sodium thiosulfate. The organic phase was washed with brine, followed by dried over anhydrous Na2SO4 and concentrated to dryness under vacuum. The crude product was chromatographed over silica gel (200–300 mesh) using hexane/AcOEt (5:1) to give compound 5 as a white solid (130 mg, 13%). IR (CH2Cl2, cm−1) νmax: 3440, 2919 (C=C-H), 1737 (C=O), 1705 (C=O), 1645 (C=O), 1517 (C=C). 1H-NMR (400 MHz, CDCl3) δ 9.43 (s, 1H, H-23), 6.11 (t, J = 5.4 Hz, 1H, NH-28), 5.26 (t, J = 3.6 Hz, 1H, H-12), 4.54 (dd, J = 14.5, 5.8 Hz, 1H, CH2-N-28), 4.23 (dd, J = 14.6, 4.7 Hz, 1H, CH2-N-28), 3.93 (dd, J = 10.1, 6.6 Hz, 1H, H-2), 3.39 (s, 3H, OCH3-2), 2.34 (dd, J = 13.2, 6.7 Hz, 1H), 1.31 (s, 3H), 1.19 (s, 3H), 1.13 (s, 3H), 0.75 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 209.38 (C-3), 199.45 (C-23), 177.57 (C-28), 140.05, 138.36, 128.68, 127.92, 127.43, 124.82 (C-12), 78.87 (C-2), 63.33 (OCH3-2), 58.36 (C-4), 53.97, 48.81, 47.74, 47.11, 43.70, 42.64, 39.71, 39.55, 39.05, 37.28, 37.02, 31.74, 30.83, 27.81, 24.75, 23.47, 23.34, 21.17, 20.01, 17.20, 17.17, 17.00, 14.21. HRMS (ESI) observed C38H54NO4 588.4060 (MH+) requires 588.4047.

3.1.7. α-Methoxy-3β-Hydroxy-23-Oxo-Urs-12-Ene-28-Benzylamide (6)

Following the procedure given for 5, compound 6 (701 mg, 70%) was obtained as a white solid (silica gel, hexane/AcOEt, 5:2). IR (CH2Cl2, cm−1) νmax: 3420, 2918 (C=C-H), 1730 (C=O), 1646 (C=O), 1521 (C=C). 1H-NMR (400 MHz, CDCl3) δ 9.35 (s, 1H, H-23), 6.14 (t, J = 5.3 Hz, 1H, NH-28), 5.24 (t, J = 3.4 Hz, 1H, H-12), 4.51 (dd, J = 14.5, 5.8 Hz, 1H, CH2-N-28), 4.21 (dd, J = 14.5, 4.6 Hz, 1H, CH2-N-28), 3.59 (d, J = 9.5 Hz, 1H, H-3), 3.40 (s, 3H, OCH3-2), 3.34 (ddd, J = 11.0, 9.4, 4.3 Hz, 1H, H-2), 2.16 (dd, J = 12.6, 4.3 Hz, 1H), 1.12 (s, 3H), 1.11 (s, 3H), 1.01 (s, 3H), 0.69 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 205.41 (C-23), 177.65 (C-28), 139.94, 138.34, 128.66, 127.91, 127.40, 125.03 (C-12), 77.87 (C-3), 75.30 (C-2), 56.75 (OCH3-2), 54.75 (C-4), 53.87, 47.69, 47.56, 47.42, 43.69, 42.57, 41.92, 39.67, 39.62, 39.04, 37.96, 37.25, 32.07, 30.84, 27.75, 24.75, 23.41, 23.34, 21.20, 19.88, 17.19, 17.04, 10.17. HRMS (ESI) observed C38H56NO4 590.4188 (MH+) requires 590.4204.

3.1.8. α-Methoxy-3β-Hydroxy-Urs-12-Ene-28-Benzylamide-23-Oic Acid (7)

Compound 6 (1 g, 1.7 mmol) was dissolved in t-BuOH (12 mL) and water (4 mL), and added 2-methyl-2-butene (1 mL), sodium dihydrogen phosphate (200 mg, 5.1 mmol) and sodium chlorite (460 mg, 5.1 mmol). After stirring at room temperature for 1 h, the reaction mixture was added aqueous solution of sodium thiosulfate, and extracted with ethyl acetate (100 mL × 3). The organic phase washed with brine followed by dried over anhydrous Na2SO4 and concentrated to dryness under vacuum. The crude product was chromatographed over silica gel (200–300 mesh) using hexane/AcOEt (1:1) to afford 7 as a white solid (957 mg, 93%). IR (CH2Cl2, cm−1) νmax: 3420, 2922 (C=C-H), 1715 (C=O), 1635 (C=O), 1525 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.19 (t, J = 5.3 Hz, 1H, NH-28), 5.23 (d, J = 3.6 Hz, 1H, H-12), 4.54 (dd, J = 14.5, 5.7 Hz, 1H, CH2-N-28), 4.21 (dd, J = 14.5, 4.4 Hz, 1H, CH2-N-28), 3.89 (d, J = 9.6 Hz, 1H, H-3), 3.41 (s, 3H, OCH3-2), 3.29 (td, J = 10.1, 9.7, 4.2 Hz, 1H, H-2), 2.13 (dd, J = 12.5, 4.3 Hz, 1H), 1.19 (s, 3H), 1.10 (s, 3H), 0.99 (s, 3H), 0.86 (d, J = 6.4 Hz, 3H), 0.69 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 181.18 (C-23), 178.00 (C-28), 139.92, 138.20, 128.67, 127.94, 127.44, 125.14 (C-12), 78.20 (C-2), 78.03 (C-3), 56.78 (OCH3-2), 53.89 (C-4), 53.15, 50.80, 47.72, 47.57, 43.79, 42.53, 42.22, 39.69, 39.56, 39.05, 37.96, 37.18, 32.25, 30.84, 27.79, 24.76, 23.40, 21.21, 20.35, 17.20, 17.13, 16.92, 12.10. HRMS (ESI) observed C38H56NO5 606.4163 (MH+) requires 606.4153.

3.1.9. α-Methoxy-3β-Acetoxy-Urs-12-Ene-28-Benzylamide-23-Oic Acid (8)

Compound 7 (300 mg, 0.5 mmol) was dissolved in pyridine (5 mL) and added acetic anhydride (0.5 mL), stirred at room temperature overnight. The reaction mixture was poured into dilute aqueous HCl (2 M), and extracted with DCM (100 mL). The organic phase was washed with dilute aqueous HCl (2 M, 200 mL), a saturated solution of sodium bicarbonate (200 mL × 2) and brine, followed by dried over anhydrous Na2SO4 and concentrated to dryness under vacuum. The crude product was chromatographed over silica gel (200–300 mesh) using hexane/AcOEt (2:1) to afford 8 as a white solid (304 mg, 94%). IR (CH2Cl2, cm−1) νmax: 3420, 2923 (C=C-H), 1739 (C=O), 1635 (C=O), 1525 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.17 (t, J = 5.2 Hz, 1H, NH-28), 5.29 (d, J = 9.9 Hz, 1H, H-3), 5.22 (d, J = 3.5 Hz, 1H, H-12), 4.53 (dd, J = 14.4, 5.6 Hz, 1H, CH2-N-28), 4.21 (dd, J = 14.5, 4.3 Hz, 1H, CH2-N-28), 3.39 (td, J = 10.9, 4.2 Hz, 1H, H-2), 3.34 (s, 3H, OCH3-2), 2.12 (dd, J = 12.7, 4.3 Hz, 1H), 2.06 (s, 3H, CH3COO-3), 1.21 (s, 3H), 1.10 (s, 3H), 1.00 (s, 3H), 0.86 (d, J = 6.3 Hz, 3H), 0.68 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 179.78 (C-23), 177.96 (C-28), 170.33 (COO-3), 139.98, 138.23, 128.67, 127.95, 127.43, 125.06 (C-12), 78.55 (C-3), 75.88 (C-2), 57.32 (OCH3-2), 53.92, 52.74, 50.34, 47.73, 47.61, 43.78, 43.51, 42.52, 39.67, 39.55, 39.05, 37.36, 37.17, 32.18, 30.84, 27.77, 24.75, 23.31, 21.20, 20.90, 20.56, 17.23, 17.03, 16.90, 12.75. HRMS (ESI) observed C40H58NO6 648.4257 (MH+) requires 648.4259.

3.1.10. α-Methoxy-3β-Hydroxy-Urs-12-Ene-28-Benzylamide-23-Methyl Ester (9)

Under a nitrogen atmosphere, compound 7 (600 mg, 1 mmol) was dissolved in dry DMF (2 mL), and K2CO3 (207 mg, 1.5 mmol) was added, and stirred for 20 min. Then CH3I (96 μL, 1.5 mmol) was added, and stirring was continued for 30 min at room temperature. The reaction mixture was neutralized with dilute aqueous HCl (1 M, 100 mL) and extracted with ethyl acetate (100 mL × 3). The combined organic phase was washed with a saturated solution of sodium bicarbonate and brine (200 mL × 3), followed by dried over anhydrous Na2SO4 and concentrated to dryness under vacuum.
The crude product was chromatographed over silica gel (200–300 mesh) using hexane/AcOEt (5:2) to afford compound 9 as a white solid (551 mg, 89%). IR (CH2Cl2, cm−1) νmax: 3420, 2921 (C=C-H), 1725 (C=O), 1639 (C=O), 1518 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.14 (t, J = 5.3 Hz, 1H, NH-28), 5.24 (t, J = 3.5 Hz, 1H, H-12), 4.54 (dd, J = 14.5, 5.9 Hz, 1H, CH2-N-28), 4.20 (dd, J = 14.5, 4.5 Hz, 1H, CH2-N-28), 3.86 (d, J = 9.6 Hz, 1H, H-3), 3.74 (s, 3H, OCH3-23), 3.40 (s, 3H, OCH3-2), 3.28 (ddd, J = 11.2, 9.6, 4.3 Hz, 1H, H-2), 2.13 (dd, J = 12.5, 4.3 Hz, 1H), 1.19 (s, 3H), 1.11 (s, 3H), 0.99 (s, 3H), 0.86 (d, J = 6.4 Hz, 3H), 0.69 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.75 (C-28), 177.24 (C-23), 139.95, 138.33, 128.67, 127.92, 127.41, 125.10 (C-12), 78.23 (C-2), 78.20 (C-3), 56.70 (OCH3-2), 53.91, 53.33, 52.30, 51.27, 47.71, 47.57, 43.71, 42.54, 42.07, 39.71, 39.58, 39.07, 38.01, 37.24, 32.27, 30.85, 27.80, 24.81, 23.38, 21.20, 20.43, 17.18, 16.89, 12.19. HRMS (ESI) observed C39H58NO5 620.4308 (MH+) requires 620.4310.

3.1.11. α-Methoxy-3β-Acetoxy-Urs-12-Ene-28-Benzylamide-23-Methyl Ester (10)

Following the procedure given for 8, compound 10 (298 mg, 90%) was obtained from compound 9 as a white solid (silica gel, hexane/AcOEt, 3:1). IR (CH2Cl2, cm−1) νmax: 3412, 2919 (C=C-H), 1735 (C=O), 1639 (C=O), 1517 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.13 (d, J = 5.2 Hz, 1H, NH-28), 5.24 (d, J = 3.6 Hz, 1H, H-3), 5.20 (d, J = 9.9 Hz, 1H, H-12), 4.54 (dd, J = 14.5, 5.5 Hz, 1H, CH2-N-28), 4.20 (dd, J = 14.4, 4.1 Hz, 1H, CH2-N-28), 3.67 (s, 3H, OCH3-23), 3.39 (ddt, J = 12.2, 6.8, 3.3 Hz, 1H, H-2), 3.34 (s, 3H, OCH3-2), 2.13 (dd, J = 12.7, 4.5 Hz, 1H), 2.05 (s, 3H, CH3COO-3), 1.22 (s, 3H), 1.12 (s, 3H), 1.00 (s, 3H), 0.69 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.74 (C-28), 175.78 (C-23), 169.96 (COO-3), 139.93, 138.34, 128.66, 127.92, 127.40, 125.06 (C-12), 78.75 (C-3), 75.86 (C-2), 57.42 (OCH3-2), 53.92, 52.97, 52.53, 50.33, 47.72, 47.59, 43.71, 43.52, 42.52, 39.70, 39.58, 39.07, 37.31, 37.26, 32.23, 30.85, 27.80, 26.91, 24.79, 23.32, 21.19, 20.95, 20.71, 17.20, 17.04, 16.87, 13.01. HRMS (ESI) observed C41H60NO6 662.4398 (MH+) requires 662.4415.

3.1.12. α-Methoxy-3-Oxo-Urs-12-Ene-28-Benzyl Amide-23-Methyl Ester (11)

Compound 9 (62 mg, 0.1 mmol) was dissolved in DCM (5 mL), added PCC (65 mg, 0.3 mmol) and stirred at room temperature overnight. The reaction mixture was added water (100 mL) and extracted with DCM. The organic phase was washed with brine, dried over anhydrous Na2SO4 and concentrated to dryness under vacuum. The crude product was chromatographed over silica gel (200–300 mesh) using hexane/AcOEt (5:1) to afford compound 10 as a white solid (28 mg, 46%). IR (CH2Cl2, cm−1) νmax: 3418, 2920 (C=C-H), 1741 (C=O), 1719 (C=O), 1640 (C=O), 1521 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.14 (t, J = 5.3 Hz, 1H, NH-28), 5.24 (t, J = 3.5 Hz, 1H, H-12), 4.54 (dd, J = 14.5, 5.8 Hz, 1H, CH2-N-28), 4.21 (dd, J = 14.6, 4.6 Hz, 1H, CH2-N-28), 3.99 (dd, J = 11.3, 6.3 Hz, 1H, H-2), 3.75 (s, 3H, OCH3-23), 3.44 (s, 3H, OCH3-2), 2.29 (td, J = 12.9, 12.1, 4.3 Hz, 2H), 1.42 (s, 3H), 1.18 (s, 3H), 1.12 (s, 3H), 0.73 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 208.25 (C-3), 177.67 (C-28), 172.83 (C-23), 140.02, 138.34, 128.67, 127.91, 127.42, 124.86 (C-12), 78.64 (C-2), 62.21 (OCH3-2), 58.43 (23-OCH3), 53.93, 52.56, 51.35, 47.72, 47.31, 46.61, 43.68, 42.58, 39.69, 39.55, 39.05, 37.26, 36.83, 31.94, 30.83, 27.84, 26.91, 24.75, 23.38, 21.18, 21.00, 17.19, 16.98, 16.76, 16.63. HRMS (ESI) observed C39H56NO5 618.4131 (MH+) requires 618.4153.

3.1.13. α-Methoxy-3β-Acetoxy-23-Oxo-Urs-12-Ene-28-Benzyl Amide (12)

Following the procedure given for 8, compound 12 (290 mg, 91%) was obtained from compound 6 as a white solid (silica gel, hexane/AcOEt, 4:1). IR (CH2Cl2, cm−1) νmax: 3376, 2923 (C=C-H), 1734 (C=O), 1640 (C=O), 1522 (C=C). 1H-NMR (400 MHz, CDCl3) δ 9.28 (s, 1H, H-23), 6.12 (t, J = 5.3 Hz, 1H, NH-28), 5.25 (t, J = 3.5 Hz, 1H, H-12), 5.02 (d, J = 9.8 Hz, 1H, H-3), 4.52 (dd, J = 14.5, 5.7 Hz, 1H, CH2-N-28), 4.22 (dd, J = 14.5, 4.6 Hz, 1H, CH2-N-28), 3.57–3.41 (m, 1H, H-2), 3.37 (s, 3H, OCH3-2), 2.19 (dd, J = 12.8, 4.6 Hz, 1H), 2.03 (s, 3H, CH3COO-3), 1.12 (s, 3H), 1.08 (s, 3H), 1.03 (s, 3H), 0.70 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 202.69 (C-23), 177.61 (C-28), 170.31 (COO-3), 139.94, 138.36, 128.66, 127.91, 127.40, 124.95 (C-12), 75.43 (C-3), 75.25 (C-2), 57.65 (OCH3-2), 55.48 (C-4), 53.90, 47.70, 47.50, 47.45, 43.67, 42.56, 39.68, 39.59, 39.05, 37.43, 37.27, 32.05, 30.83, 27.76, 26.91, 24.76, 23.31, 21.19, 20.87, 19.95, 17.21, 16.99, 16.95, 10.35. HRMS (ESI) observed C40H58NO5 632.4316 (MH+) requires 632.4310.

3.1.14. α-Methoxy-3β-Hydroxy-Urs-12-Ene-28-Benzyl Amide-23-Amide (13a)

To a solution of compound 7 (60 mg, 0.1 mmol) in dry DMF (1 mL), HOBt (25 mg, 0.2 mmol), EDCI·HCl (20 mg, 0.12 mmol), DIPEA (20 μL) and NH4HCO3 (15.8 mg, 0.2 mmol) was added, stirring at 85 °C overnight. The reaction mixture was poured into the brine, and extracted with ethyl acetate (100 mL × 3). The organic phase was washed with a saturated solution of sodium bicarbonate and brine (200 mL × 3), dried over Na2SO4 and concentrated to dryness under vacuum. The crude product was purified by column chromatography over silica gel (200–300 mesh) using hexane/AcOEt (1:4) to afford compound 13a as a white solid (51 mg, 84%). IR (CH2Cl2, cm−1) νmax: 3361, 2919 (C=C-H), 1643 (C=O), 1522 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.16 (t, J = 5.4 Hz, 1H, NH-28), 6.14 (s, 1H, NH-23), 5.87 (s, 1H, NH-23), 5.23 (t, J = 3.4 Hz, 1H, H-12), 4.54 (dd, J = 14.5, 5.8 Hz, 1H, CH2-N-28), 4.19 (dd, J = 14.6, 4.4 Hz, 1H, CH2-N-28), 3.82 (d, J = 9.5 Hz, 1H, H-3), 3.40 (s, 3H, OCH3-2), 3.26 (tt, J = 11.3, 5.6 Hz, 1H, H-2), 2.70 (br s, 1H, OH-3), 2.09 (dd, J = 12.4, 4.1 Hz, 1H), 1.23 (s, 3H), 1.10 (s, 3H), 1.00 (s, 3H), 0.85 (d, J = 6.4 Hz, 3H), 0.68 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 179.63 (C-28), 177.80 (C-23), 140.02, 138.36, 128.65, 127.89, 127.39, 125.05 (C-12), 78.34 (C-2), 77.70 (C-3), 56.75 (OCH3-2), 53.92, 52.57, 50.39, 47.71, 47.56, 43.69, 42.57, 41.90, 39.68, 39.59, 39.07, 37.79, 37.25, 32.30, 30.84, 27.78, 24.81, 23.46, 23.38, 21.19, 20.17, 17.28, 17.21, 16.95, 12.50. HRMS (ESI) observed C38H57N2O4 605.4309 (MH+) requires 605.4313.

3.1.15. α-Methoxy-3β-Hydroxy-Urs-12-Ene-28-Benzyl Amide-23-Methylamide (13b)

As described for 13a, compound 13b (43 mg, 70%) was obtained from methylamine hydrochloride as a white solid (silica gel, hexane/AcOEt, 1:3). IR (CH2Cl2, cm−1) νmax: 3377, 2919 (C=C-H), 1636 (C=O), 1534 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.15 (t, J = 5.2 Hz, 1H, NH-28), 6.05 (q, J = 4.8 Hz, 1H, NH-23), 5.23 (t, J = 3.5 Hz, 1H, H-12), 4.55 (dd, J = 14.5, 5.9 Hz, 1H, CH2-N-28), 4.19 (dd, J = 14.5, 4.4 Hz, 1H, CH2-N-28), 3.86 (d, J = 9.7 Hz, 1H, H-3), 3.39 (s, 3H, OCH3-2), 3.34–3.18 (m, 1H, H-2), 2.85 (d, J = 4.5 Hz, 3H, CH3-N-23), 1.20 (s, 3H), 1.11 (s, 3H), 1.00 (s, 3H), 0.86 (d, J = 6.4 Hz, 3H), 0.69 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.83 (C-28), 177.04 (C-23), 140.06, 138.36, 128.66, 127.90, 127.39, 125.07 (C-12), 78.40 (C-2), 77.59 (C-3), 56.55 (OCH3-2), 53.95, 52.36, 50.40, 47.73, 47.55, 43.70, 42.60, 41.69, 39.68, 39.60, 39.08, 37.77, 37.25, 32.34, 30.85, 27.80, 26.87, 24.83, 23.43, 23.39, 21.19, 20.17, 17.29, 17.20, 16.97, 12.19. HRMS (ESI) observed C39H59N2O4 619.4471 (MH+) requires 619.4469.

3.1.16. α-Methoxy-3β-Hydroxy-Urs-12-Ene-28-Benzyl Amide-23-Ethylamide (13c)

As described for 13a, compound 13c (38 mg, 60%) was obtained from ethylamine as a white solid (silica gel, hexane/AcOEt, 1:1). IR (CH2Cl2, cm−1) νmax: 3372, 2922 (C=C-H), 1636 (C=O), 1528 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.15 (t, J = 5.2 Hz, 1H, NH-28), 5.97 (t, J = 5.5 Hz, 1H, NH-23), 5.23 (t, J = 3.4 Hz, 1H, H-12), 4.55 (dd, J = 14.5, 5.9 Hz, 1H, CH2-N-28), 4.19 (dd, J = 14.6, 4.4 Hz, 1H, CH2-N-28), 3.85 (d, J = 9.7 Hz, 1H, H-3), 3.39 (s, 3H, OCH3-2), 3.37–3.21 (m, 1H, H-2), 2.09 (dd, J = 12.4, 4.3 Hz, 1H), 1.11 (s, 3H), 0.99 (s, 3H), 0.85 (d, J = 6.4 Hz, 3H), 0.68 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.85 (C-28), 176.16 (C-23), 140.05, 138.35, 128.65, 127.90, 127.39, 125.09 (C-12), 78.45 (C-2), 77.53 (C-3), 56.58 (OCH3-2), 53.94, 52.15, 50.39, 47.73, 47.55, 43.70, 42.59, 41.74, 39.68, 39.59, 39.08, 37.77, 37.24, 34.88, 32.33, 30.85, 27.79, 24.83, 23.42, 23.39, 21.19, 20.07, 17.29, 17.20, 16.96, 14.80, 12.21. HRMS (ESI) observed C40H61N2O4 633.4599 (MH+) requires 633.4626.

3.1.17. α-Methoxy-3β-Hydroxy-Urs-12-Ene-28-Benzyl Amide-23-Isopropylamide (13d)

As described for 13a, compound 13d (48 mg, 75%) was obtained from isopropylamine as a white solid (silica gel, hexane/AcOEt, 3:2). IR (CH2Cl2, cm−1) νmax: 3372, 2923 (C=C-H), 1637 (C=O), 1522 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.16 (t, J = 5.3 Hz, 1H, NH-28), 5.73 (d, J = 7.7 Hz, 1H, NH-23), 5.22 (t, J = 3.5 Hz, 1H, H-12), 4.54 (dd, J = 14.6, 5.9 Hz, 1H, CH2-N-28), 4.18 (dd, J = 14.6, 4.4 Hz, 1H, CH2-N-28), 3.84 (d, J = 9.7 Hz, 1H, H-3), 3.38 (s, 3H, OCH3-2), 3.34–3.20 (m, 1H, H-2), 2.42 (br s, 1H, OH-3), 2.08 (dd, J = 12.4, 4.3 Hz, 1H), 1.10 (s, 3H), 0.99 (s, 3H), 0.85 (d, J = 6.4 Hz, 3H), 0.68 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.84 (C-28), 175.33 (C-23), 140.04, 138.36, 128.64, 127.89, 127.37, 125.09 (C-12), 78.47 (C-2), 77.49 (C-3), 56.58 (OCH3-2), 53.93, 51.96, 50.31, 47.72, 47.54, 43.69, 42.59, 41.77, 41.73, 39.68, 39.59, 39.07, 37.76, 37.24, 32.31, 30.85, 27.79, 24.82, 23.43, 23.39, 22.83, 22.59, 21.19, 20.02, 17.28, 17.20, 16.96, 12.23. HRMS (ESI) observed C41H63N2O4 647.4764 (MH+) requires 647.4782.

3.1.18. α-Methoxy-3β-Hydroxy-Urs-12-Ene-28-Benzyl Amide-23-Propargylamide (13e)

As described for 13a, compound 13e (50 mg, 78%) was obtained from propargylamine as a white solid (silica gel, hexane/AcOEt, 1:1). IR (CH2Cl2, cm−1) νmax: 3372, 2923 (C=C-H), 1640 (C=O), 1520 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.28 (t, J = 5.2 Hz, 1H, NH-23), 6.15 (t, J = 5.3 Hz, 1H, NH-28), 5.22 (t, J = 3.4 Hz, 1H, H-12), 4.54 (dd, J = 14.5, 5.9 Hz, 1H, CH2-N-28), 4.19 (dd, J = 14.6, 4.4 Hz, 1H, CH2-N-28), 4.16–4.10 (m, 1H), 3.99 (ddd, J = 17.5, 4.6, 2.6 Hz, 1H), 3.81 (d, J = 9.7 Hz, 1H, H-3), 3.38 (s, 3H, OCH3-2), 3.27 (td, J = 10.1, 9.5, 4.1 Hz, 1H, H-2), 2.23 (t, J = 2.5 Hz, 1H), 1.21 (s, 3H), 1.10 (s, 3H), 0.99 (s, 3H), 0.85 (d, J = 6.4 Hz, 3H), 0.68 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.80 (C-28), 176.39 (C-23), 140.03, 138.35, 128.65, 127.89, 127.38, 125.04 (C-12), 79.80 (alkyne), 78.36 (C-2), 77.48 (C-3), 71.51 (terminal alkyne), 56.63 (OCH3-2), 53.92, 52.31, 50.58, 47.71, 47.55, 43.69, 42.57, 41.73, 39.67, 39.58, 39.06, 37.80, 37.25, 32.27, 30.84, 29.75, 27.78, 24.81, 23.41, 23.38, 21.19, 20.11, 17.29, 17.20, 16.96, 12.19. HRMS (ESI) observed C41H59N2O4 643.4473 (MH+) requires 643.4469.

3.1.19. N-(2α-Methoxy-3β-Hydroxy-Urs-12-Ene-28-Benzylamide-23-Oyl)-l-Alanine Methyl Ester (13f)

As described for 13a, compound 13f (45 mg, 65%) was obtained from l-alanine methyl ester as a white solid (silica gel, hexane/AcOEt, 1:1). IR (CH2Cl2, cm−1) νmax: 3437, 2918 (C=C-H), 1738 (C=O), 1637 (C=O), 1523 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.55 (d, J = 7.0 Hz, 1H, NH-23), 6.15 (m, 1H, NH-28), 5.23 (t, J = 3.4 Hz, 1H, H-12), 4.58 (d, J = 7.0 Hz, 1H), 4.55 (dd, J = 14.5, 5.9 Hz, 1H, CH2-N-28), 4.19 (dd, J = 14.5, 4.4 Hz, 1H, CH2-N-28), 3.77 (d, J = 9.7 Hz, 1H, H-3), 3.76 (s, 3H, CH3-ester), 3.41 (s, 3H, OCH3-2), 3.29 (ddd, J = 11.2, 9.6, 4.3 Hz, 1H, H-2), 2.16–2.05 (m, 1H), 1.43 (d, J = 7.2 Hz, 3H), 1.25 (s, 3H), 1.10 (s, 3H), 1.01 (s, 3H), 0.85 (d, J = 6.4 Hz, 3H), 0.69 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.82 (C-28), 176.42 (C-23), 173.97 (amino acid ester), 140.04, 138.36, 128.65, 127.90, 127.38, 125.09 (C-12), 78.02 (C-2), 77.85 (C-3), 56.84 (OCH3-2), 53.93, 52.52, 52.47, 50.01, 48.73, 47.72, 47.61, 43.69, 42.58, 42.09, 39.68, 39.60, 39.07, 37.64, 37.24, 32.29, 30.85, 27.79, 24.82, 23.42, 23.37, 21.20, 20.28, 18.06, 17.32, 17.21, 16.98, 12.09. HRMS (ESI) observed C42H63N2O6 691.4665 (MH+) requires 691.4681.

3.1.20. N-(2α-Methoxy-3β-Hydroxy-Urs-12-Ene-28-Benzylamide-23-Oyl)-l-Valine Methyl Ester (13g)

As described for 13a, compound 13g (40 mg, 56%) was obtained from l-valine methyl ester as a white solid (silica gel, hexane/AcOEt, 1:1). IR (CH2Cl2, cm−1) νmax: 3438, 2919 (C=C-H), 1738 (C=O), 1643 (C=O), 1517 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.52 (d, J = 8.1 Hz, 1H, NH-23), 6.16 (t, J = 5.2 Hz, 1H, NH-28), 5.23 (t, J = 3.5 Hz, 1H, H-12), 4.62–4.43 (m, 1H, CH2-N-28), 4.19 (dd, J = 14.6, 4.4 Hz, 1H, CH2-N-28), 3.77 (d, J = 9.7 Hz, 1H, H-3), 3.75 (s, 3H, CH3-ester), 3.41 (s, 3H, OCH3-2), 3.28 (ddd, J = 11.3, 9.6, 4.2 Hz, 1H, H-2), 2.20 (pd, J = 6.9, 4.6 Hz, 1H), 1.11 (s, 3H), 1.02 (s, 3H), 0.85 (d, J = 6.4 Hz, 3H), 0.69 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.84 (C-28), 176.88 (C-23), 172.87 (amino acid ester), 140.07, 138.36, 128.65, 127.90, 127.38, 125.09 (C-12), 78.04 (C-2), 77.94 (C-3), 57.83, 56.88 (OCH3-2), 53.94, 52.67, 52.21, 49.78, 47.73, 47.66, 43.69, 42.60, 42.04, 39.67, 39.65, 39.07, 37.61, 37.24, 32.31, 30.84, 27.78, 24.83, 23.41, 23.38, 21.19, 20.52, 19.06, 18.07, 17.35, 17.21, 17.03, 12.21. HRMS (ESI) observed C44H67N2O6 719.4993 (MH+) requires 719.4994.

3.1.21. N-(2α-Methoxy-3β-Hydroxy-Urs-12-Ene-28-Benzylamide-23-oyl)-l-Phenylalanine Methyl Ester (13h)

As described for 13a, compound 13h (37 mg, 48%) was obtained from l-phenylalanine methyl ester as a white solid (silica gel, hexane/AcOEt, 2:1). IR (CH2Cl2, cm−1) νmax: 3396, 2919 (C=C-H), 1740 (C=O), 1638 (C=O), 1517 (C=C). 1H-NMR (400 MHz, CDCl3) δ 7.20–7.06 (m, 2H), 6.41 (d, J = 7.5 Hz, 1H, NH-23), 6.15 (t, J = 5.2 Hz, 1H, NH-28), 5.22 (t, J = 3.2 Hz, 1H, H-12), 4.87 (q, J = 6.7 Hz, 1H), 4.55 (dd, J = 14.6, 5.5 Hz, 1H, CH2-N-28), 4.19 (m, 1H, CH2-N-28), 3.74 (s, 3H, CH3-ester), 3.70 (d, J = 9.6 Hz, 1H, H-3), 3.39 (s, 3H, OCH3-2), 3.30–3.20 (m, 1H, H-2), 3.20–3.05 (m, 2H), 1.14 (s, 3H), 1.09 (s, 3H), 0.66 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.86 (C-28), 176.55 (C-23), 172.51(amino acid ester), 140.05, 138.34, 129.11, 128.66, 128.62, 127.91, 127.40, 127.14, 125.09 (C-12), 78.00 (C-2), 77.85 (C-3), 56.81 (OCH3-2), 53.94, 53.63, 52.55, 52.43, 49.88, 47.74, 47.60, 43.72, 42.55, 41.97, 39.68, 39.59, 39.08, 37.85, 37.59, 37.25, 32.32, 30.85, 27.81, 24.82, 23.44, 23.36, 21.20, 20.13, 17.28, 17.22, 17.00, 12.01. HRMS (ESI) observed C48H67N2O6 767.4978 (MH+) requires 767.4994.

3.1.22. N-(2α-Methoxy-3β-Hydroxy-Urs-12-Ene-28-Benzylamide-23-Oyl)-4-Aminobutyric Ethyl Ester (13i)

As described for 13a, compound 13i (32 mg, 45%) was obtained from 4-aminobutyric ethyl ester as a white solid (silica gel, hexane/AcOEt, 1:2). IR (CH2Cl2, cm−1) νmax: 3361, 2924 (C=C-H), 1732 (C=O), 1634 (C=O), 1526 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.33 ((t, J = 5.5 Hz, 1H, NH-23), 6.15 (t, J = 5.3 Hz, 1H, NH-28), 5.22 (d, J = 3.6 Hz, 1H, H-12), 4.53 (dd, J = 14.5, 5.7 Hz, 1H, CH2-N-28), 4.25–4.04 (m, 3H), 3.80 (d, J = 9.5 Hz, 1H, H-3), 3.38 (s, 3H, OCH3-2), 2.64 (br s, 1H, OH-3), 2.43–2.29 (m, 2H), 2.08 (dd, J = 12.5, 4.1 Hz, 1H), 1.18 (s, 3H), 0.84 (d, J = 6.4 Hz, 3H), 0.67 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.98 (C-28), 176.67 (C-23), 173.65 (amino acid ester), 139.96, 138.22, 128.65, 127.88, 127.40, 125.13 (C-12), 78.42 (C-2), 77.55 (C-3), 60.56, 56.63 (OCH3-2), 53.90, 52.37, 50.33, 47.71, 47.54, 43.73, 42.55, 41.80, 39.66, 39.57, 39.04, 37.73, 37.19, 32.29, 31.82, 30.82, 27.74, 24.78, 24.32, 23.37, 21.18, 20.15, 17.29, 17.18, 16.92, 14.23, 12.12. HRMS (ESI) observed C44H67N2O6 719.4978 (MH+) requires 719.4994.

3.1.23. α-Methoxy-3β-Hydroxy-Urs-12-Ene-28-Benzyl Amide-23-Dimethylamide (13j)

As described for 13a, compound 13j (51 mg, 80%) was obtained from dimethyamine hydrochloride as a white solid (silica gel, hexane/AcOEt, 2:3). IR (CH2Cl2, cm−1) νmax: 3372, 2921 (C=C-H), 1630 (C=O), 1522 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.16 (t, J = 5.3 Hz, 1H, NH-28), 5.22 (t, J = 3.4 Hz, 1H, H-12), 4.53 (dd, J = 14.5, 5.9 Hz, 1H, CH2-N-28), 4.18 (dd, J = 14.5, 4.5 Hz, 1H, CH2-N-28), 4.10 (d, J = 9.5 Hz, 1H, H-3), 3.39 (s, 3H, OCH3-2), 3.28 (ddd, J = 11.2, 9.4, 4.2 Hz, 1H, H-2), 3.07 (s, 6H, dimethyl-23), 2.09 (dd, J = 12.6, 4.5 Hz, 1H), 1.33 (s, 3H), 1.08 (s, 3H), 0.84 (d, J = 6.4 Hz, 3H), 0.68 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.82 (C-28), 177.49 (C-23), 139.97, 138.36, 128.65, 127.90, 127.38, 125.15 (C-12), 79.22 (C-2), 78.42 (C-3), 56.62 (OCH3-2), 54.27, 53.93, 51.76, 47.73, 47.56, 43.69, 42.61, 42.09, 39.70, 39.67, 39.41, 39.07, 38.08, 37.24, 32.29, 30.85, 27.79, 24.82, 23.41, 23.33, 21.19, 20.79, 17.20, 17.11, 16.98, 15.99. HRMS (ESI) observed C40H61N2O4 633.4620 (MH+) requires 633.4626.

3.1.24. α-Methoxy-3β-Hydroxy-Urs-12-Ene-28-Benzylamide-23- (4-Methyl-1-Piperazinyl)-Amide (13k)

As described for 13a, compound 13k (48 mg, 70%) was obtained from methylpiperazine as a white solid (silica gel, DCM/MeOH, 30:1). IR (CH2Cl2, cm−1) νmax: 3393, 2922 (C=C-H), 1630 (C=O), 1523 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.13 (t, J = 5.2 Hz, 1H, NH-28), 5.24 (t, J = 3.5 Hz, 1H, H-12), 4.55 (dd, J = 14.6, 5.9 Hz, 1H, CH2-N-28), 4.20 (dd, J = 14.6, 4.5 Hz, 1H, CH2-N-28), 3.96 (d, J = 9.5 Hz, 1H, H-3), 3.72 (s, 4H), 3.40 (s, 3H, OCH3-2), 3.27 (ddd, J = 11.1, 9.4, 4.2 Hz, 1H, H-2), 2.44 (q, J = 4.9 Hz, 4H), 2.32 (s, 3H), 2.10 (dd, J = 12.4, 4.2 Hz, 1H), 1.12 (s, 3H), 1.02 (s, 3H), 0.86 (d, J = 6.4 Hz, 3H), 0.71 (s, 3H). 13C-NMR (126 MHz, CDCl3) δ 177.79 (C-28), 177.79 (C-23), 140.04, 138.40, 128.68, 127.92, 127.41, 125.14 (C-12), 78.52 (C-2), 78.52 (C-3), 56.66 (OCH3-2), 55.35, 54.17, 53.95, 51.34, 47.83, 47.74, 46.18, 45.92, 45.83, 43.70, 42.67, 41.91, 39.69, 39.51, 39.08, 38.03, 37.27, 32.37, 30.86, 27.80, 24.85, 23.41, 23.35, 21.20, 20.88, 17.21, 17.12, 15.44, 8.77. HRMS (ESI) observed C43H66N3O4 688.5028 (MH+) requires 688.5048.

3.1.25. α-Methoxy-3β-Acetoxy-Urs-12-Ene-28-Benzyl Amide-23-Amide (14a)

As described for 13a, compound 14a (52 mg, 80%) was obtained from 8 (65 mg, 0.1 mmol) and NH4HCO3 as a white solid (silica gel, hexane/AcOEt, 2:3). IR (CH2Cl2, cm−1) νmax: 3451, 2917 (C=C-H), 1735 (C=O), 1654 (C=O), 1537 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.15 (t, J = 5.3 Hz, 1H, NH-28), 6.15 (br s, 1H, NH-23), 5.85 (br s, 1H, NH-23), 5.28 (d, J = 9.9 Hz, 1H, H-3), 5.23 (t, J = 3.6 Hz, 1H, H-12), 4.53 (dd, J = 14.5, 5.8 Hz, 1H, CH2-N-28), 4.20 (dd, J = 14.5, 4.4 Hz, 1H, CH2-N-28), 3.39 (td, J = 10.7, 4.3 Hz, 1H, H-2), 3.32 (s, 3H, OCH3-2), 2.11 (dd, J = 12.7, 4.4 Hz, 1H), 2.05 (s, 3H, CH3COO-3), 1.09 (s, 3H), 1.02 (s, 3H), 0.86 (d, J = 6.4 Hz, 3H), 0.68 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.73 (C-28), 177.72 (C-23), 169.93 (COO-3), 139.98, 138.36, 128.65, 127.88, 127.39, 124.98 (C-12), 78.54 (C-3), 76.19 (C-2), 57.07 (OCH3-2), 53.88, 52.43, 51.23, 47.70, 47.58, 43.68, 43.18, 42.51, 39.67, 39.54, 39.05, 37.60, 37.26, 32.26, 30.82, 27.77, 24.78, 23.40, 23.36, 21.20, 21.03, 19.97, 17.29, 17.24, 16.87, 13.22. HRMS (ESI) observed C40H59N2O5 647.4413 (MH+) requires 647.4418.

3.1.26. α-Methoxy-3β-Acetoxy-Urs-12-Ene-28-Benzyl Amide-23-Methylamide (14b)

As described for 13a, compound 14b (49 mg, 74%) was obtained from 8 (65 mg, 0.1 mmol) and methylamine hydrochloride as a white solid (silica gel, hexane/AcOEt, 2:3). IR (CH2Cl2, cm−1) νmax: 3404, 2920 (C=C-H), 1735 (C=O), 1640 (C=O), 1529 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.15 (t, J = 5.3 Hz, 1H, NH-28), 6.05 (q, J = 4.7 Hz, 1H, NH-23), 5.28–5.19 (m, 2H, H-3 and H-12), 4.53 (dd, J = 14.5, 5.9 Hz, 1H, CH2-N-28), 4.19 (dd, J = 14.5, 4.5 Hz, 1H, CH2-N-28), 3.39 (td, J = 10.7, 4.3 Hz, 1H, H-2), 3.31 (s, 3H, OCH3-2), 2.78 (d, J = 4.5 Hz, 3H, CH3-N-23), 2.10 (dd, J = 12.7, 4.4 Hz, 1H), 2.03 (s, 3H, CH3COO-3), 1.24 (s, 3H), 1.09 (s, 3H), 1.01 (s, 3H), 0.86 (d, J = 6.4 Hz, 3H), 0.67 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.77 (C-28), 175.26 (C-23), 169.76 (COO-3), 139.99, 138.34, 128.66, 127.88, 127.40, 125.01 (C-12), 78.63 (C-3), 76.22 (C-2), 57.03 (OCH3-2), 53.91, 52.40, 51.12, 47.71, 47.57, 43.68, 43.13, 42.53, 39.67, 39.55, 39.06, 37.50, 37.27, 32.30, 30.83, 27.78, 26.98, 24.79, 23.39, 23.35, 21.19, 21.01, 20.07, 17.31, 17.22, 16.87, 13.02. HRMS (ESI) observed C41H61N2O5 661.4560 (MH+) requires 661.4575.

3.1.27. α-Methoxy-3β-Acetoxy-Urs-12-Ene-28-Benzyl Amide-23-Ethylamide (14c)

As described for 13a, compound 14c (47 mg, 70%) was obtained from 8 (65 mg, 0.1 mmol) and ethylamine as a white solid (silica gel, hexane/AcOEt, 3:2). IR (CH2Cl2, cm−1) νmax: 3372, 2924 (C=C-H), 1740 (C=O), 1639 (C=O), 1526 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.14 (t, J = 5.3 Hz, 1H, NH-28), 5.88 (t, J = 5.5 Hz, 1H, NH-23), 5.32–5.13 (m, 2H, H-3 and H-12), 4.54 (dd, J = 14.5, 5.9 Hz, 1H, CH2-N-28), 4.19 (dd, J = 14.6, 4.5 Hz, 1H, CH2-N-28), 3.39 (td, J = 10.8, 10.4, 4.2 Hz, 1H, H-2), 3.32 (s, 3H, OCH3-2), 3.26–3.15 (m, 1H), 2.11 (dd, J = 12.7, 4.4 Hz, 1H), 2.04 (s, 3H, CH3COO-3), 1.23 (s, 3H), 1.02 (s, 3H), 0.86 (d, J = 6.4 Hz, 3H), 0.68 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.78 (C-28), 174.30 (C-23), 169.66 (COO-3), 140.01, 138.36, 128.65, 127.89, 127.38, 125.00 (C-12), 78.53 (C-3), 76.19 (C-2), 57.03 (OCH3-2), 53.91, 52.26, 51.04, 47.71, 47.64, 43.68, 43.20, 42.53, 39.68, 39.56, 39.07, 37.46, 37.26, 34.86, 32.32, 30.84, 27.78, 24.80, 23.36, 21.19, 20.96, 20.03, 17.33, 17.23, 16.89, 14.82, 12.98. HRMS (ESI) observed C41H61N2O5 675.4712 (MH+) requires 675.4731.

3.1.28. α-Methoxy-3β-Acetoxy-Urs-12-Ene-28-Benzyl Amide-23-Isopropylamide (14d)

As described for 13a, compound 14d (58 mg, 84%) was obtained from 8 (65 mg, 0.1 mmol) and isopropylamine as a white solid (silica gel, hexane/AcOEt, 2:1). IR (CH2Cl2, cm−1) νmax: 3403, 2921 (C=C-H), 1740 (C=O), 1637 (C=O), 1526 (C=C).1 H-NMR (400 MHz, CDCl3) δ 6.15 (t, J = 5.3 Hz, 1H, NH-28), 5.61 (d, J = 7.7 Hz, 1H, NH-23), 5.25–5.19 (m, 2H, H-3 and H-12), 4.54 (dd, J = 14.5, 5.9 Hz, 1H, CH2-N-28), 4.19 (dd, J = 14.6, 4.5 Hz, 1H, CH2-N-28), 4.13–3.97 (m, 1H), 3.44–3.33 (m, 1H, H-2), 3.32 (s, 3H, OCH3-2), 2.11 (dd, J = 12.7, 4.4 Hz, 1H), 2.03 (s, 3H, CH3COO-3), 1.21 (s, 3H), 1.01 (s, 3H), 0.86 (d, J = 6.4 Hz, 3H), 0.67 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 177.78 (C-28), 173.42 (C-23), 169.56 (COO-3), 140.01, 138.37, 128.64, 127.88, 127.37, 125.01 (C-12), 78.46 (C-3), 76.17 (C-2), 57.02 (OCH3-2), 53.91, 52.13, 51.00, 47.71, 47.67, 43.67, 43.22, 42.52, 41.63, 39.67, 39.56, 39.06, 37.43, 37.25, 32.34, 30.84, 27.77, 24.79, 23.34, 22.73, 22.55, 21.19, 20.92, 20.02, 17.33, 17.22, 16.89, 12.92. HRMS (ESI) observed C42H65N2O5 689.4893 (MH+) requires 689.4888.

3.1.29. α-Methoxy-3β-Acetoxy-Urs-12-Ene-28-Benzyl Amide-23-Propargylamide (14e)

As described for 13a, compound 14e (54 mg, 79%) was obtained from 8 (65 mg, 0.1 mmol) and propargylamine as a white solid (silica gel, hexane/AcOEt, 3:1). IR (CH2Cl2, cm−1) νmax: 3379, 2922 (C=C-H), 1737 (C=O), 1643 (C=O), 1521 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.16 (t, J = 5.3 Hz, 1H, NH-28), 6.15 (t, J = 5.2 Hz, 1H, NH-23), 5.34–5.16 (m, 2H, H-3 and H-12), 4.54 (dd, J = 14.5, 5.8 Hz, 1H, CH2-N-28), 4.19 (dd, J = 14.5, 4.4 Hz, 1H, CH2-N-28), 4.08 (ddd, J = 17.5, 5.5, 2.6 Hz, 1H), 3.95 (ddd, J = 17.5, 4.6, 2.5 Hz, 1H), 3.39 (td, J = 10.8, 4.4 Hz, 1H, H-2), 3.32 (s, 3H, OCH3-2), 2.22 (t, J = 2.5 Hz, 1H), 2.11 (dd, J = 12.7, 4.4 Hz, 1H), 2.04 (s, 3H, CH3COO-3), 1.10 (s, 3H), 1.02 (s, 3H), 0.86 (d, J = 6.4 Hz, 3H), 0.68 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.77 (C-28), 174.49 (C-23), 169.72 (COO-3), 140.01, 138.35, 128.66, 127.89, 127.40, 124.97 (C-12), 79.70 (alkyne), 78.39 (C-3), 76.10 (C-2), 71.46 (terminal alkyne), 57.08 (OCH3-2), 53.92, 52.47, 51.04, 47.72, 47.61, 43.69, 43.15, 42.54, 39.68, 39.55, 39.07, 37.49, 37.26, 32.24, 30.84, 29.77, 27.79, 24.79, 23.37, 21.20, 21.00, 20.07, 17.34, 17.22, 16.89, 12.89. HRMS (ESI) observed C43H61N2O5 685.4553 (MH+) requires 685.4575.

3.1.30. N-(2α-Methoxy-3β-Acetoxy-Urs-12-Ene-28-Benzylamide-23-oyl)-l-Alanine Methyl Ester (14f)

As described for 13a, compound 14f (62 mg, 84%) was obtained from 8 (65 mg, 0.1 mmol) and l-alanine methyl ester as a white solid (silica gel, hexane/AcOEt, 5:2). IR (CH2Cl2, cm−1) νmax: 3391, 2921 (C=C-H), 1742 (C=O), 1640 (C=O), 1525 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.39 (d, J = 7.2 Hz, 1H, NH-23), 6.14 (t, J = 5.4 Hz, 1H, NH-28), 5.23 (t, J = 3.9 Hz, 1H, H-12), 5.19 (d, J = 9.9 Hz, 1H, H-3), 4.56 (ddd, J = 14.4, 11.3, 6.6 Hz, 2H), 4.19 (dd, J = 14.6, 4.4 Hz, 1H, CH2-N-28), 3.74 (s, 3H, CH3-ester), 3.39 (td, J = 10.8, 4.3 Hz, 1H, H-2), 3.33 (s, 3H, OCH3-2), 2.04 (s, 3H, CH3COO-3), 1.03 (s, 3H), 0.86 (d, J = 6.4 Hz, 3H), 0.68 (d, J = 2.3 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.80 (C-28), 174.11 (C-23), 173.62 (amino acid ester), 169.85 (COO-3), 140.04, 138.36, 128.65, 127.90, 127.39, 124.98 (C-12), 78.30 (C-3), 76.12 (C-2), 57.13 (OCH3-2), 53.93, 52.40, 52.23, 50.95, 48.30, 47.72, 43.69, 43.24, 42.55, 39.68, 39.57, 39.07, 37.43, 37.25, 32.24, 30.84, 27.77, 24.80, 23.35, 21.19, 20.96, 20.10, 18.35, 17.30, 17.23, 16.92, 12.84. HRMS (ESI) observed C44H65N2O7 733.4770 (MH+) requires 733.4786.

3.1.31. N-(2α-Methoxy-3β-Acetoxy-Urs-12-Ene-28-Benzylamide-23-Oyl)-l-Valine Methyl Ester (14g)

As described for 13a, compound 14g (57 mg, 75%) was obtained from 8 (65 mg, 0.1 mmol) and l-valine methyl ester as a white solid (silica gel, hexane/AcOEt, 4:1). IR (CH2Cl2, cm−1) νmax: 3420, 2959, 2921 (C=C-H), 1741 (C=O), 1638 (C=O), 1515 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.28 (d, J = 8.3 Hz, 1H, NH-23), 6.15 (t, J = 5.2 Hz, 1H, NH-28), 5.24 (t, J = 3.4 Hz, 1H, H-12), 5.17 (d, J = 9.9 Hz, 1H, H-3), 4.62–4.44 (m, 2H), 4.19 (dd, J = 14.6, 4.4 Hz, 1H, CH2-N-28), 3.73 (s, 3H, CH3-ester), 3.39 (td, J = 10.8, 4.3 Hz, 1H, H-2), 3.33 (s, 3H, OCH3-2), 2.04 (s, 3H, CH3COO-3), 1.12 (s, 3H), 1.03 (s, 3H), 0.86 (d, J = 6.4 Hz, 3H), 0.68 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.84 (C-28), 174.63 (C-23), 172.74 (amino acid ester), 169.76 (COO-3), 140.07, 138.35, 128.65, 127.90, 127.39, 124.99 (C-12), 78.26 (C-3), 76.19 (C-2), 57.41, 57.09 (OCH3-2), 53.95, 52.52, 52.11, 50.66, 47.73, 47.71, 43.69, 43.12, 42.57, 39.68, 39.58, 39.07, 37.35, 37.24, 32.19, 31.14, 30.84, 27.76, 24.81, 23.34, 21.19, 20.96, 20.29, 18.98, 17.83, 17.31, 17.23, 16.94, 12.80. HRMS (ESI) observed C46H69N2O7 761.5092 (MH+) requires 761.5099.

3.1.32. N-(2α-Methoxy-3β-Acetoxy-Urs-12-Ene-28-Benzylamide-23-Oyl)-l-Phenylalanine Methyl Ester (14h)

As described for 13a, compound 14h (47 mg, 58%) was obtained from 8 (65 mg, 0.1 mmol) and l-phenylalanine methyl ester as a white solid (silica gel, hexane/AcOEt, 4:1). IR (CH2Cl2, cm−1) νmax: 3373, 2953, 2921 (C=C-H), 1742 (C=O), 1640 (C=O), 1525 (C=C). 1H-NMR (400 MHz, CDCl3) δ 7.17–7.07 (m, 3H, ), 6.16 (d, J = 7.5 Hz, 1H, NH-23), 6.15 (t, J = 5.2 Hz, 1H, NH-28), 5.23 (t, J = 3.5 Hz, 1H, H-12), 5.14 (d, J = 10.0 Hz, 1H, H-3), 4.90 (dt, J = 7.9, 6.1 Hz, 1H), 4.55 (dd, J = 14.5, 5.9 Hz, 1H, CH2-N-28 ), 4.20 (dd, J = 14.5, 4.4 Hz, 1H, CH2-N-28), 3.72 (s, 3H, CH3-ester), 3.36 (dt, J = 10.8, 5.4 Hz, 1H, H-2), 3.31 (s, 3H, OCH3-2), 3.20–3.00 (m, 3H), 2.08 (dd, J = 12.7, 4.4 Hz, 1H), 2.00 (s, 3H, CH3COO-3), 1.18 (s, 3H), 0.99 (s, 3H), 0.67 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.81 (C-28), 174.22 (C-23), 172.17 (amino acid ester), 169.74 (COO-3), 140.06, 138.37, 135.94, 129.18, 128.65, 128.57, 127.90, 127.39, 127.11, 124.97 (C-12), 78.23 (C-3), 76.00 (C-2), 57.07 (OCH3-2), 53.94, 52.97, 52.29, 52.26, 50.28, 47.74, 47.63, 43.69, 43.08, 42.53, 39.68, 39.55, 39.09, 38.03, 37.26, 32.24, 31.51, 30.85, 30.14, 27.80, 24.81, 23.39, 23.32, 21.20, 20.89, 20.03, 17.24, 16.94, 12.60. HRMS (ESI) observed C50H69N2O7 809.5068 (MH+) requires 809.5099.

3.1.33. N-(2α-Methoxy-3β-Acetoxy-Urs-12-Ene-28-Benzylamide-23-Oyl)-4-Aminobutyric Ethyl Ester (14i)

As described for 13a, compound 14i (49 mg, 64%) was obtained from 8 (65 mg, 0.1 mmol) and 4-aminobutyric ethyl ester as a white solid (silica gel, hexane/AcOEt, 3:2). IR (CH2Cl2, cm−1) νmax: 3372, 2924 (C=C-H), 1737 (C=O), 1639 (C=O), 1525 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.26 (t, J = 5.5 Hz, 1H, NH-23), 6.14 (t, J = 5.4 Hz, 1H, NH-28), 5.30–5.15 (m, 2H, H-3 and H-12), 4.54 (dd, J = 14.5, 5.8 Hz, 1H, CH2-N-28), 4.29–3.98 (m, 3H, CH2-N-28 and CH2-ester), 3.38 (m, 1H, H-2), 3.32 (s, 3H, OCH3-2), 3.19 (dq, J = 13.0, 6.6 Hz, 1H), 2.34 (t, J = 7.0 Hz, 2H), 2.11 (dd, J = 12.7, 4.4 Hz, 1H), 1.10 (s, 3H), 1.01 (s, 3H), 0.86 (d, J = 6.4 Hz, 3H), 0.68 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.76 (C-28), 174.70 (C-23), 173.66 (amino acid ester), 169.67 (COO-3), 140.01, 138.36, 128.65, 127.89, 127.38, 125.01 (C-12), 78.57 (C-3), 76.19 (C-2), 60.59, 57.05 (OCH3-2), 53.92, 52.37, 51.02, 47.71, 47.63, 43.68, 43.20, 42.53, 39.67, 39.56, 39.06, 37.46, 37.25, 32.30, 31.86, 30.83, 27.78, 24.79, 24.27, 23.34, 21.18, 20.95, 20.09, 17.29, 17.22, 16.89, 14.22, 12.89. HRMS (ESI) observed C46H69N2O7 761.5096 (MH+) requires 761.5099.

3.1.34. α-Methoxy-3β-Acetoxy-Urs-12-Ene-28-Benzyl Amide-23-Dimethylamide (14j)

As described for 13a, compound 14j (42 mg, 62%) was obtained from 8 (65 mg, 0.1 mmol) and dimethyamine hydrochloride as a white solid (silica gel, hexane/AcOEt, 1:1). IR (CH2Cl2, cm−1) νmax: 3411, 2920 (C=C-H), 1740 (C=O), 1632 (C=O), 1522 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.12 (t, J = 5.2 Hz, 1H, NH-28), 5.58 (d, J = 9.3 Hz, 1H, H-3), 5.24 (q, J = 6.0, 4.7 Hz, 1H, H-12), 4.53 (dd, J = 14.6, 5.7 Hz, 1H, CH2-N-28), 4.21 (dd, J = 14.5, 4.6 Hz, 1H, CH2-N-28), 3.36 (s, 3H, OCH3-2), 3.16 (s, 4H), 2.05 (s, 3H, CH3COO-3), 1.11 (s, 3H), 1.04 (s, 3H), 0.87 (d, J = 6.4 Hz, 3H), 0.70 (s, 3H). 13C-NMR (101 MHz, MeOD) δ 178.37 (C-28), 174.31 (C-23), 170.73 (COO-3), 138.94, 138.64, 128.03, 127.57, 126.68, 125.18 (H-12), 76.87 (C-3), 76.54 (C-2), 65.24, 56.67 (OCH3-2), 53.67, 52.88, 49.25, 47.88, 42.99, 41.95, 39.42, 39.15, 38.89, 37.36, 32.45, 30.57, 30.37, 29.47, 27.55, 23.82, 23.10, 22.80, 20.30, 19.53, 18.91, 16.42, 16.15, 15.04, 12.79. HRMS (ESI) observed C42H63N2O5 670.4709 (MH+) requires 675.4731.

3.1.35. α-Methoxy-3β-Acetoxy-Urs-12-Ene-28-Benzylamide-23-(4-Methyl-1-Piperazinyl)-Amide (14k)

As described for 13a, compound 14k (33 mg, 45%) was obtained from 8 (65 mg, 0.1 mmol) and methylpiperazine as a white solid (silica gel, hexane/AcOEt, 1:3). IR (CH2Cl2, cm−1) νmax: 3383, 2925 (C=C-H), 1740 (C=O), 1635 (C=O), 1522 (C=C). 1H-NMR (400 MHz, CDCl3) δ 6.13 (t, J = 5.4 Hz, 1H, NH-28), 5.51 (d, J = 9.3 Hz, 1H, H-3), 5.23 (d, J = 3.7 Hz, 1H, H-12), 4.50 (ddd, J = 14.7, 6.0, 2.5 Hz, 1H, CH2-N-28), 4.20 (dd, J = 14.5, 4.5 Hz, 1H, CH2-N-28), 3.89 (s, 1H), 3.67 (s, 2H), 3.41 (d, J = 10.2 Hz, 1H, H-2), 3.34 (s, 3H, OCH3-2), 2.55–2.33 (m, 4H), 2.28 (d, J = 1.8 Hz, 3H), 2.22–2.09 (m, 1H), 2.02 (s, 3H, CH3COO-3), 1.09 (s, 3H), 1.01 (s, 3H), 0.85 (d, J = 6.3 Hz, 3H), 0.68 (d, J = 2.2 Hz, 3H). 13C-NMR (101 MHz, CDCl3) δ 177.56 (C-28), 172.21 (C-23), 170.17 (COO-3), 139.82, 138.35, 128.63, 127.89, 127.38, 125.05 (C-12), 77.30, 60.36, 57.65 (OCH3-2), 54.94, 53.86, 53.57, 50.23, 48.53, 47.69, 46.25, 45.77, 43.66, 43.41, 42.54, 39.68, 39.01, 37.44, 37.21, 32.50, 30.83, 27.79, 24.75, 23.43, 23.32, 21.19, 21.02, 20.41, 17.18, 17.04, 16.95, 16.00, 14.20. HRMS (ESI) observed C45H68N3O5 730.5144 (MH+) requires 730.5153.

3.2. Biology

3.2.1. Materials

All cell lines were obtained from the China State Institute of Pharmaceutical Industry (SIPI) (Shanghai). Fetal Bovine Serum (FBS) and Dulbecco’s Modified Eagle Medium (DMEM) with penicillin and streptomycin were obtained from PAA Laboratories GmbH (Pashing, Austria). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was obtained from Amresco. A Cell Counting Kit-8 (CCK-8) was obtained from Beyotime Biotechnology (Shanghai, China). DMSO was obtained from Merck (Darmstadt, Germany). Doxorubicin was obtained from Iffect Chemphar Co., Ltd (Nanjing, China).

3.2.2. In-Vitro Cytotoxicity of Human Cancer Cell Lines

HCT116, SKOV-3, A549, A2780, HepG2, HL-60 and MCF-7 cells were incubated in DMEM with 10% heat-inactivated FBS in a humidified atmosphere of 5.0% CO2 at 37 °C. The in-vitro cytotoxicity of AA derivatives was determined using MTT assay. A 100-μL volume of culture medium at a concentration of 3 × 104 cell/mL was added to 96-well plate wells, which were maintained in a humidified atmosphere of 5.0% CO2 at 37 °C. After 24 h, 10 μL solution of AA derivatives and doxorubicin dissolved in DMSO and phophate buffered saline (PBS) and then diluted with DMEM under a concentration gradient, was added in the wells for final concentrations of 100, 10, 1, 0.1, 0.01, 0.001 μM of compounds in HCT116 and SKOV-3 cells and 125, 25, 5, 1, 0.2, 0.04 μM in A549, A2780, HepG2, HL-60 and MCF-7 cells. After 72 h incubation in a humidified atmosphere of 5.0% CO2 at 37 °C, 20 μl MTT solution (5 mg/mL) was added into each well and the cells were incubated. After 4 h, 100 μL HCl aqueous solution (0.01 M) with 10% SDS and 5% isobutanol was added into each well to dissolve the precipitated formazan and the absorbance was read at 570 nm on Thermo Scientific Varioskan Flash plate reader. All IC50 values were averaged from three independent experiments.

3.2.3. In-Vitro Cytotoxicity of Human Normal Cell Line

HUVEC cell lines were incubated in DMEM with 10% heat-inactivated FBS in a humidified atmosphere of 5.0% CO2 at 37 °C. The in-vitro cytotoxicity of AA derivatives was determined using CCK-8. A 100-μL volume of culture medium at a concentration of 3 × 104 cell/mL was added to 96-well plate wells, and these were maintained in a humidified atmosphere of 5.0% CO2 at 37 °C. After 24 h, 10 μL solution of AA derivatives dissolved in DMSO and PBS and then diluted with DMEM under a concentration gradient was added to the wells for final concentrations of 125, 25, 5, 1, 0.2, 0.04 μM. After 72 h incubation in a humidified atmosphere of 5.0% CO2 at 37 °C, 10 μl CCK-8 solution was added into each well and the cells were incubated for another 1 h, and the absorbance was read at 450 nm. All cell viability levels were averaged from three independent experiments.

4. Conclusions

In this paper, we reported a highly selective oxidation method on the C-23 hydroxyl group in an AA derivative, and then, for the first time with AA derivatives, the C-23 carboxyl group was modified to synthesize a series of novel AA derivatives. The selective oxidation method provided a high-yield route for more modification in the C-3 hydroxyl, C-23 aldehyde and C-23 carboxyl groups in AA.
The 23-amide AA derivatives 10, 14j and 14k exhibited good cytotoxic activities against tumor cell lines but were significantly less cytotoxic against normal human cell line, showing excellent selectivity.
We studied the intramolecular hydrogen bonds of the 23-amide AA derivatives via exhaustive NMR characterization, and combined with their cytotoxic activities against SKOV-3 and HCT116 cell lines, which revealed a distinctive SAR associated with the intramolecular hydrogen bonding of the amide moiety at C-23. We found that the 23-amide AA derivatives, which fixed the amide hydrogen atom in the AA skeleton through intramolecular hydrogen bonding, showed rather good cytotoxic activities. Intramolecular hydrogen bond has been actively applied in drug design for its effects on receptor binding and its improved molecular properties, such as membrane permeability, water solubility, and lipophilicity. When a donor and an acceptor are in proximity on the same molecule, an equilibrium may exist between closed conformations in which an intramolecular hydrogen bond is formed, creating a temporary ring system, and open conformations in which the polar groups are exposed to solvent. The closed forms, hiding polarity from the environment, should be more lipophilic and might display a higher membrane permeability, whereas the open forms should be more water-soluble [33]. Especially for the triterpenoids, with a rigid skeleton that often leads to poor water solubility, dynamic and proper water solubility and lipophilicity may be crucial for activity and the pharmacokinetic profile. In this paper, these active AA derivatives with intramolecular hydrogen bonds in the A ring, can function as ideal starting points for further modification to develop compounds with better activities and improved molecular properties.

Supplementary Materials

Supplementary Information shows the NMR spectra of compounds 1-14 and the NMR titration of 13b and 14b.

Author Contributions

Y.X. and C.-g.H. designed the experiments; Y.-h.L., M.-c.C., F.L., Z.X. and X.-t.T. performed the experiments; Y.-h.L. and C.-g.H. wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding

The current study was supported by National Science and Technology Major Project of the Ministry of Science and Technology of China (No. 2019ZX09201001-001-008), Youth Innovation Promotion Association of Chinese Academy of Sciences (No. 2019280), the National Natural Science Foundation of China for Young Scientists (No. 81803828) and the General Financial Grant from China Postdoctoral Science Foundation (No. 2018M642123).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bhuwan, B.M.; Vinod, K.T. Natural Products: An Evolving Role in Future Drug Discovery. Eur. J. Med. Chem. 2011, 46, 4769–4807. [Google Scholar]
  2. Marie-Hélène, T.; François, G.; Mario, D.; Marc, D. Anticancer Bioactivity of Compounds from Medicinal Plants Used in European Medieval Traditions. Biochem. Pharmacol. 2013, 86, 1239–1247. [Google Scholar]
  3. Liu, J. Pharmacology of Oleanolic Acid and Ursolic Acid. J. Ethnopharmacol. 1995, 49, 57–68. [Google Scholar] [CrossRef]
  4. Yong, S.L.; Da-Qing, J.; Eun, J.K.; Seung, H.P.; Eung-Seok, L.; Tae, C.J.; Doo, H.N.; Keun, H.; Jung-Ae, K. Asiatic Acid, a Triterpene, Induces Apoptosis through Intracellular Ca2+ Release and Enhanced Expression of P53 in Hepg2 Human Hepatoma Cells. Cancer Lett. 2002, 186, 83–91. [Google Scholar]
  5. Byung, C.P.; Kefa, O.B.; Eung-Seok, L.; Yong, S.L.; Jung-Ae, K. Asiatic Acid Induces Apoptosis in Sk-Mel-2 Human Melanoma Cells. Cancer Lett. 2005, 218, 81–90. [Google Scholar]
  6. Fernando, J.R.; Josep, J.C.; José, A.L.; Marta, C. (2α,3β)-2,3-Dihydroxyolean-12-En-28-Oic Acid, a New Natural Triterpene from Olea Europea, Induces Caspase Dependent Apoptosis Selectively in Colon Adenocarcinoma Cells. FEBS Lett. 2006, 580, 6302–6310. [Google Scholar]
  7. Andres, P.; Francisco, R.; Samuel, M.F.; Andres, G.G.; Antonio, M. Maslinic Acid Derivatives Induce Significant Apoptosis in B16f10 Murine Melanoma Cells. Eur. J. Med. Chem. 2011, 46, 5991–6001. [Google Scholar]
  8. Brinkhaus, B.; Lindner, M.; Schuppan, D.; Hahn, E.G. Chemical, Pharmacological and Clinical Profile of the East Asian Medical Plant Centella Aslatica. Phytomedicine 2000, 7, 427–448. [Google Scholar] [CrossRef]
  9. Min, K.C.; Min-A, S.; Dong, S.K.; Hyung, G.P.; Sang, S.J.; Sang, G.K. 2-Oxo-3,23-Isopropylidene-Asiatate (As2006a), a Wound-Healing Asiatate Derivative, Exerts Anti-Inflammatory Effect by Apoptosis of Macrophages. Int. Immunopharmacol. 2003, 3, 1429–1437. [Google Scholar]
  10. Shukla, A.; Rasik, A.M.; Jain, G.K.; Shankar, R.; Kulshrestha, D.K.; Dhawan, B.N. In Vitro and in Vivo Wound Healing Activity of Asiaticoside Isolated from Centella Asiatica. J. Ethnopharmacol. 1999, 65, 1–11. [Google Scholar] [CrossRef]
  11. Jing, G.; Xinhui, T.; Huan, D.; Yimei, F.; Xiaoning, Z.; Qiang, X. Hepatoprotective Activity of Terminalia Catappa L. Leaves and Its Two Triterpenoids. J. Pharm. Pharmacol. 2004, 56, 1449–1455. [Google Scholar]
  12. Dae, S.J.; Ga, Y.L.; Junghyun, K.; Yun, M.L.; Jong, M.K.; Young, S.K.; Jin, S.K. A New Pancreatic Lipase Inhibitor Isolated from the Roots of Actinidia Arguta. Arch. Pharmacal. Res. 2008, 31, 666–670. [Google Scholar]
  13. Shyh-Shyun, H.; Chuan-Sung, C.; Hsien-Jung, C.; Wen-Chi, H.; Ming-Jyh, S.; Ying-Chih, L.; Pei-Hsin, S.; Guan-Jhong, H. Antinociceptive Activities and the Mechanisms of Anti-Inflammation of Asiatic Acid in Mice. Evid. Based Complement. Alternat Med. 2011, 2011. [Google Scholar] [CrossRef] [Green Version]
  14. Fan, Y.M.; Xu, L.Z.; Gao, J.; Wang, Y.; Tang, X.H.; Zhao, X.N.; Zhang, Z.X. Phytochemical and Antiinflammatory Studies on Terminalia Catappa. Fitoterapia 2004, 75, 253–260. [Google Scholar] [CrossRef]
  15. Cho, C.W.; Choi, D.S.; Cardone, M.H.; Kim, C.W.; Sinskey, A.J.; Rha, C. Glioblastoma Cell Death Induced by Asiatic Acid. Cell Biol. Toxicol. 2006, 22, 393–408. [Google Scholar] [CrossRef]
  16. Jian-Fei, L.; Ri-Zhen, H.; Gui-Yang, Y.; Man-Yi, Y.; Heng-Shan, W.; Ying-Ming, P.; Jing-Teng, X. Synthesis and Biological Evaluation of Novel Aniline-Derived Asiatic Acid Derivatives as Potential Anticancer Agents. Eur. J. Med. Chem. 2014, 86, 175–188. [Google Scholar]
  17. Ri-Zhen, H.; Gui-Bin, L.; Mei-Shan, L.; Yi-Lin, F.; Shi-Feng, Z.; Mei-Mei, Z.; Zhi-Xin, L.; Jing, S.; Heng-Shan, W. Synthesis and Discovery of Asiatic Acid Based 1,2,3-Triazole Derivatives as Antitumor Agents Blocking Nf-Kappab Activation and Cell Migration. Medchemcomm 2019, 10, 584–597. [Google Scholar]
  18. Ri-Zhen, H.; Cai-Yi, W.; Jian-Fei, L.; Gui-Yang, Y.; Ying-Ming, P.; Man-Yi, Y.; Heng-Shan, W.; Ye, Z. Synthesis, Antiproliferative and Apoptosis-Inducing Effects of Novel Asiatic Acid Derivatives Containing A-Aminophosphonates. RSC Adv. 2016, 6, 62890–62906. [Google Scholar]
  19. Yue, J.; Gang, W.; Ying, G.; Minjie, X.; Zhunan, G. Synthesis, Anti-Tumor and Anti-Angiogenic Activity Evaluations of Asiatic Acid Amino Acid Derivatives. Molecules 2015, 20, 7309–7324. [Google Scholar]
  20. Sven, S.; Lucie, H.; Julia, K.; René, C. Selective Killing of Cancer Cells with Triterpenoic Acid Amides—The Substantial Role of an Aromatic Moiety Alignment. Eur. J. Med. Chem. 2016, 122, 452–464. [Google Scholar]
  21. Bruno, M.F.G.; Jorge, A.R.S.; Silvia, M.; Marta, C. Synthesis and Anticancer Activity of Novel Fluorinated Asiatic Acid Derivatives. Eur. J. Med. Chem. 2016, 114, 101–117. [Google Scholar]
  22. Loc, T.V.; Quynh, N.V.T.; Chien, T.V.; Phuong, T.T.T.; Ninh, P.T.; Thanh, N.T.; Thu, H.L.T.; Nga, T.N.; Thao, D.T.; Sung, T.V. Synthesis of Asiatic Acid Derivatives and Their Cytotoxic Activity. Med. Chem. Res. 2018, 27, 1609–1623. [Google Scholar]
  23. Zhao, C.-H.; Zhang, C.-L.; Shi, J.-J.; Hou, X.-Y.; Feng, B.; Zhao, L.-X. Design, Synthesis, and Biofunctional Evaluation of Novel Pentacyclic Triterpenes Bearing O-[4-(1-Piperazinyl)-4-Oxo-Butyryl Moiety as Antiproliferative Agents. Bioorg. Med. Chem. Lett. 2015, 25, 4500–4504. [Google Scholar]
  24. Yong, L.; Fang, Y.; Mingxing, Y.; Lijuan, J.; Li, Y.; Xiaowei, Z.; Ying, L.; Lin, D.; Xu, B.; Shufan, Y. Synthesis and Evaluation of Asiatic Acid Derivatives as Anti-Fibrotic Agents: Structure/Activity Studies. Steroids 2105, 96, 44–49. [Google Scholar]
  25. Byeong-Seon, J.; Young, C.K.; Eung-Seok, L. Modification of C2,3,23,28 Functional Groups on Asiatic Acid and Evaluation of Hepatoprotective Effects. ChemInform 2007, 38, 977–982. [Google Scholar]
  26. Byeong-Seon, J.; Mi, K.L.; Young, C.K.; Eung-Seok, L. Modification of C2 Functional Group On. Asiatic Acid and the Evaluation of Hepatoprotective Effects. Arch. Pharm. Res. 2007, 30, 282–289. [Google Scholar]
  27. Bianka, S.; Elke, P.; Anja, O.; René, C. Towards Cytotoxic and Selective Derivatives of Maslinic Acid. Bioorg. Med. Chem. 2014, 22, 594–615. [Google Scholar]
  28. Stefan, B.; Matthias, F.M. Triterpenoid Saponins of the Caryophyllaceae and Illecebraceae Family. Phytochem. Lett. 2011, 4, 59–68. [Google Scholar]
  29. Safiye, E.; Tamer, K.; Aysun, Ç.; Ozgen, A.; Ali, O.; Esin, P. Synthesis, Antimicrobial and Cytotoxic Activities, and Structure-Activity Relationships of Gypsogenin Derivatives against Human Cancer Cells. Eur. J. Med. Chem. 2014, 82, 565–573. [Google Scholar]
  30. Lucie, H.; Stefan, S.; Björn, A.W.; René, C. Gypsogenin Derivatives: An Unexpected Class of Inhibitors of Cholinesterases. Arch. Pharm. (Weinheim) 2014, 347, 707–716. [Google Scholar]
  31. Guiying, W.; Haiping, C.; Jilei, W.; Yanling, M.; Jingyong, S. Synthesis of Gypsogenin and Gypsogenic Acid Derivatives with Antitumor Activity by Damaging Cell Membranes. New J. Chem. 2019, 43, 18898–18914. [Google Scholar]
  32. Michael, K.; Jana, W.; Lucie, F.; Sven, S.; René, C. Transformation of Asiatic Acid into a Mitocanic, Bimodal-Acting Rhodamine B Conjugate of Nanomolar Cytotoxicity. Eur. J. Med. Chem. 2018, 159, 143–148. [Google Scholar]
  33. Bernd, K.; Peter, M.; Martin, S. Intramolecular Hydrogen Bonding in Medicinal Chemistry. J. Med. Chem. 2010, 53, 2601–2611. [Google Scholar]
Sample Availability: Samples of the compounds are not available.
Molecules 25 03709 g001 550
Figure 1. Chemical structure of asiatic acid (AA), EM2 and gypsogenin.
Figure 1. Chemical structure of asiatic acid (AA), EM2 and gypsogenin.
Molecules 25 03709 g001
Molecules 25 03709 sch001 550
Scheme 1. Reagents and conditions: (a) p-TsOH·H2O, 2,2-dimethoxypropane, dry acetone, rt, 12 h, 85%; (b) HATU, DIPEA, benzyl amine, dry DMF, 60 °C, 12 h, 62%; (c) NaH, CH3I, dry DMF, rt, 30 min, 97%; (d) 1M aq. HCl, rt, 30 min, 98%; (e) DMP, dry DCM, rt, 5: 13%, 6: 70%; (f) Ac2O, pyridine, rt, 12 h, 100%; (g) 2-methyl-2-butene, NaH2PO4, NaClO2, t-BuOH, H2O, rt, 1 h, 93%; (h) K2CO3, CH3I, dry DMF, rt, 30 min, 89%; (i) PCC, DCM, rt, 12 h, 46%; (j) HOBt, EDCI·HCl, DIPEA, amine, dry DMF, 85 °C, 12 h, 45–84%.
Scheme 1. Reagents and conditions: (a) p-TsOH·H2O, 2,2-dimethoxypropane, dry acetone, rt, 12 h, 85%; (b) HATU, DIPEA, benzyl amine, dry DMF, 60 °C, 12 h, 62%; (c) NaH, CH3I, dry DMF, rt, 30 min, 97%; (d) 1M aq. HCl, rt, 30 min, 98%; (e) DMP, dry DCM, rt, 5: 13%, 6: 70%; (f) Ac2O, pyridine, rt, 12 h, 100%; (g) 2-methyl-2-butene, NaH2PO4, NaClO2, t-BuOH, H2O, rt, 1 h, 93%; (h) K2CO3, CH3I, dry DMF, rt, 30 min, 89%; (i) PCC, DCM, rt, 12 h, 46%; (j) HOBt, EDCI·HCl, DIPEA, amine, dry DMF, 85 °C, 12 h, 45–84%.
Molecules 25 03709 sch001
Molecules 25 03709 g002 550
Figure 2. Three possible intramolecular hydrogen bonding modes for compounds 13 or 14. Mode (A): the hydrogen bonds connecting 3β-OH donor with 2α-OCH3 acceptor and connecting NH-23 donor with 3β-OH acceptor; Mode (B): the hydrogen bond connecting 3β-OH donor with 23-carbonyl acceptor; Mode (C): the hydrogen bond connecting NH-23 donor with 3β-acetoxy acceptor.
Figure 2. Three possible intramolecular hydrogen bonding modes for compounds 13 or 14. Mode (A): the hydrogen bonds connecting 3β-OH donor with 2α-OCH3 acceptor and connecting NH-23 donor with 3β-OH acceptor; Mode (B): the hydrogen bond connecting 3β-OH donor with 23-carbonyl acceptor; Mode (C): the hydrogen bond connecting NH-23 donor with 3β-acetoxy acceptor.
Molecules 25 03709 g002
Molecules 25 03709 g003 550
Figure 3. Cell viability of compounds 10, 14j and 14k on the human normal cell line (HUVEC). * p < 0.05 vs. control.
Figure 3. Cell viability of compounds 10, 14j and 14k on the human normal cell line (HUVEC). * p < 0.05 vs. control.
Molecules 25 03709 g003
Table
Table 1. Cytotoxic activities (IC50)a of AA, AA derivatives and doxorubicin against human ovarian (SKOV-3) and colon (HCT-116) cancer cell lines under the treatment with six increasing concentrations of each compound for 72 h. Abbreviation: N.D., not determined.
Table 1. Cytotoxic activities (IC50)a of AA, AA derivatives and doxorubicin against human ovarian (SKOV-3) and colon (HCT-116) cancer cell lines under the treatment with six increasing concentrations of each compound for 72 h. Abbreviation: N.D., not determined.
Molecules 25 03709 i001
IC50 (μM)
CompoundR2R1SKOV-3HCT116
5 Molecules 25 03709 i002H>10025.99 ± 6.68
6OHHN.D.8.46 ± 1.64
7OHOH31.91 ± 2.5916.71 ± 1.68
9OHOCH36.81 ± 3.873.07 ± 1.48
10OAcOCH3N.D.1.08 ± 0.66
11 Molecules 25 03709 i003OCH3>100>100
12OAcH>1006.69 ± 1.15
13aOHNH2N.D.7.45 ± 1.62
13bOH Molecules 25 03709 i004N.D.7.45 ± 3.53
13cOH Molecules 25 03709 i005N.D.10.95 ± 4.28
13dOH Molecules 25 03709 i006N.D.8.57 ± 3.04
13eOH Molecules 25 03709 i0076.72 ± 4.328.03 ± 2.79
13fOHHNCH(CH3)COOCH33.09 ± 1.544.35 ± 1.05
13gOH(CH3)2CH(NH)COOCH3N.D.9.69 ± 1.64
13hOHPhCH2CH(HN)COOCH3>100>50
13iOHHN(CH2)3COOCH2CH3N.D.15.23 ± 1.99
13jOH Molecules 25 03709 i008N.D.9.6 ± 4.58
14aOAcNH27.12 ± 2.616.52 ± 3.03
14bOAc Molecules 25 03709 i009N.D.34.24 ± 7.87
14cOAc Molecules 25 03709 i010>100>100
14dOAc Molecules 25 03709 i011>100>100
14eOAc Molecules 25 03709 i012>100>100
14fOAcHNCH(CH3)COOCH3>100>50
14gOAc(CH3)2CH(NH)COOCH3>100>100
14hOAcPhCH2CH(HN)COOCH3>100>100
14iOAcHN(CH2)3COOCH2CH3>100>100
14jOAc Molecules 25 03709 i013N.D.1.83 ± 0.91
AA20.51 ± 4.0624.64 ± 3.26
Doxorubicin0.08 ± 0.010.03 ± 0.02
(IC50)a (μM) values are expressed as the mean ± SD of three independent experiments.
Table
Table 2. 13C-NMR and 1H-NMR signals of the positions about intramolecular hydrogen bond in compounds 13 and 14 (CDCl3).
Table 2. 13C-NMR and 1H-NMR signals of the positions about intramolecular hydrogen bond in compounds 13 and 14 (CDCl3).
C-2C-3C-23NH-23 (4.85 mM)
13a78.3477.70177.805.945.44
14a76.1978.54177.725.825.43
Δδ13a–δ14a2.15−0.840.080.120.01
13b78.4077.59177.045.96
14b76.2278.63175.265.84
Δδ13b–δ14b2.18−1.041.780.12
13c78.4577.53176.165.90
14c76.1978.53174.305.81
Δδ13c–δ14c2.26−1.001.860.09
13d78.4777.49175.335.71
14d76.1778.46173.425.60
Δδ13d–δ14d2.30−0.971.910.11
13e78.3677.48176.396.13
14e76.1078.39174.495.98
Δδ13e–δ14e2.26−0.911.900.15
13f78.0277.85176.426.53
14f76.1278.30174.116.39
Δδ13f–δ14f1.90−0.452.310.14
13g78.0477.94176.886.53
14g76.1978.26174.636.28
Δδ13g–δ14g1.85–0.322.250.25
13h78.0077.85176.556.40
14h76.0078.23174.226.17
Δδ13h–δ14h2.00–0.382.330.23
13i78.4277.55176.676.22
14i76.1978.57174.706.21
Δδ13i–δ14i2.23–1.021.970.01
Table
Table 3. Cytotoxic activities (IC50)a of compounds 10, 13k, 14j and 14k against five human cancer cell lines and one human normal cell line under the treatment with six increasing concentrations of each compound for 72 h.
Table 3. Cytotoxic activities (IC50)a of compounds 10, 13k, 14j and 14k against five human cancer cell lines and one human normal cell line under the treatment with six increasing concentrations of each compound for 72 h.
CompoundIC50 (μM)
A549A2780HepG2HL-60MCF-7HUVEC
10>1251.28 ± 0.321.43 ± 0.320.47 ± 0.083.99 ± 1.21>125
14j6.72 ± 0.642.24 ± 0.523.77 ± 1.223.01 ± 0.445.89 ± 1.33>125
13k5.70 ± 0.5812.97± 1.182.22 ± 0.6810.73 ± 2.082.85 ± 0.25N.D.
14k4.04 ± 0.514.31 ± 0.582.84 ± 0.463.36 ±0.661.78 ± 0.38>125
AA41.02 ± 0.87 [17]28.2 ± 0.3 [32]35.37 ± 1.47 [17]N.D.68.5 ± 2.50 [21]>100 [16]
(IC50)a (μM) values are expressed as the mean ± SD of three independent experiments.

Share and Cite

MDPI and ACS Style

Lu, Y.-h.; Chen, M.-c.; Liu, F.; Xu, Z.; Tian, X.-t.; Xie, Y.; Huang, C.-g. Synthesis and Cytotoxic Activity of Novel C-23-Modified Asiatic Acid Derivatives. Molecules 2020, 25, 3709. https://doi.org/10.3390/molecules25163709

AMA Style

Lu Y-h, Chen M-c, Liu F, Xu Z, Tian X-t, Xie Y, Huang C-g. Synthesis and Cytotoxic Activity of Novel C-23-Modified Asiatic Acid Derivatives. Molecules. 2020; 25(16):3709. https://doi.org/10.3390/molecules25163709

Chicago/Turabian Style

Lu, Yi-hong, Ming-cang Chen, Fang Liu, Zhou Xu, Xiao-ting Tian, Yang Xie, and Cheng-gang Huang. 2020. "Synthesis and Cytotoxic Activity of Novel C-23-Modified Asiatic Acid Derivatives" Molecules 25, no. 16: 3709. https://doi.org/10.3390/molecules25163709

Article Metrics

Back to TopTop